CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
11093886,110938864,4,F,,20220321,20150506,20220324,EXP,,GB-BMSGILMSD-2015-0151479,GILEAD,"Bulman J, Teo SY, Page E. An uncommon cause of anaemia in pregnancy: A case report of emtricitabine-induced pure red cell aplasia. HIV Medicine. 2015;Volume 16, Sup2:21-24",39,YR,A,F,Y,,,20220324,,HP,GB,GB,EFAVIRENZ,Aplasia pure red cell;Maternal exposure during pregnancy;Off label use,110938864,OT,,,,,,,,,110938864,1,HIV infection
11739131,1173913110,10,F,,20220202,20151113,20220215,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-17476250,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20220215,,HP,FR,FR,EFAVIRENZ,Foetal exposure during pregnancy;Pachygyria,1173913110,OT,,,,,,,,,1173913110,1,Product used for unknown indication
11991033,1199103318,18,F,,20220307,20160202,20220315,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-004939,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20220315,,CN,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,1199103318,OT,,,,,,,,,1199103318,1,HIV infection
12285931,122859312,2,F,,20220321,20160420,20220331,EXP,,GB-009507513-1505GBR001885,MERCK,"Bulman J. An uncommon cause of anaemia in pregnancy: A case report of emtricitabine-induced pure red cell aplasia. HIV Medicine. 2015;16, Sup2:30-1",39,YR,,F,Y,,,20220331,,HP,GB,GB,EFAVIRENZ,Aplasia pure red cell;Maternal exposure during pregnancy;Off label use,122859312,OT,,,,,,,,,122859312,1,HIV infection
12741534,1274153411,11,F,,20220307,20160914,20220314,EXP,,CA-ROCHE-1829817,ROCHE,,54,YR,,M,Y,,,20220314,,HP,CA,,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,1274153411,DE,,,,,,,,,1274153411,1,Product used for unknown indication
14165912,141659123,3,F,,20220307,20171107,20220309,EXP,,GB-GILEAD-2017-0303084,GILEAD,,85,YR,E,M,Y,,,20220309,,MD,GB,GB,EFAVIRENZ,Drug interaction;Renal impairment,141659123,OT,,,141659123,1,,,152,DAY,141659123,1,HIV infection
14246609,142466099,9,F,,20220302,20171204,20220316,EXP,,GB-AUROBINDO-AUR-APL-2017-43959,AUROBINDO,,85,YR,,M,Y,,,20220316,,MD,GB,GB,EFAVIRENZ,Drug interaction;Renal impairment,142466099,OT,,,,,,,,,142466099,1,Cardiovascular event prophylaxis
14248948,142489487,7,F,,20220216,20171204,20220222,EXP,,GB-MYLANLABS-2017M1075159,MYLAN,,85,YR,,M,Y,,,20220222,,MD,GB,GB,EFAVIRENZ,Drug interaction;Renal impairment,142489487,OT,,,,,,,,,142489487,1,Cardiovascular event prophylaxis
14277495,142774953,3,F,,20220307,20171212,20220314,EXP,,GB-SHIRE-GB201732945,TAKEDA,,85,YR,,M,Y,,,20220314,,CN,GB,GB,EFAVIRENZ,Drug interaction;Renal impairment,142774953,OT,,,,,,,,,142774953,1,Inflammatory bowel disease
14306973,1430697312,12,F,,20220211,20171220,20220223,EXP,,CA-APOTEX-2017AP022582,APOTEX,,54,YR,,M,Y,,,20220223,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities;Product use in unapproved indication,1430697312,OT,,,,,,,,,1430697312,1,Bipolar disorder
14318341,143183413,3,F,,20220202,20171222,20220216,EXP,,GB-AUROBINDO-AUR-APL-2017-46773,AUROBINDO,,85,YR,,M,Y,,,20220216,,MD,GB,GB,EFAVIRENZ,Drug interaction;Renal impairment,143183413,OT,,,,,,,,,143183413,1,Cardiovascular event prophylaxis
14366162,143661624,4,F,,20220318,20180109,20220329,EXP,,CA-009507513-1801CAN001991,MERCK,Unknown. Unknown. Unknown,,,,,Y,,,20220329,,HP,CA,CA,EFAVIRENZ,Acute kidney injury;Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Blood bilirubin increased;Cerebral ischaemia;Cystitis noninfective;Drug interaction;Febrile neutropenia;Haematuria;Infection;Myalgia;Pulmonary embolism;Seizure;Thrombosis;Tumour lysis syndrome;Vomiting,143661624,OT,,,,,,,,,143661624,1,HIV infection
15238115,152381157,7,F,20140101,20220228,20180803,20220308,EXP,,ES-AUROBINDO-AUR-APL-2018-039058,AUROBINDO,"Bravo I, Alvarez H, Marino A, Clotet B, Molto J.. Recurrent coronary disease in HIV-infected patients: role of drug?drug interactions. British Journal of Clinical Pharmacology. 2018;84 (7):1617-1619",39,YR,,M,Y,,,20220308,,MD,ES,ES,EFAVIRENZ,Acute coronary syndrome;Acute myocardial infarction;Chest pain;Drug interaction;Vascular stent thrombosis,152381157,HO,,,152381157,1,2014,,,,152381157,1,Antiplatelet therapy
15448433,154484334,4,F,,20220304,20180929,20220317,EXP,,PT-AUROBINDO-AUR-APL-2018-047799,AUROBINDO,"Soares J, Santos JV, Sarmento A, Costa-Pereira A.. Spontaneous Viral Clearance in Sixteen HIV-Infected Patients with Chronic Hepatitis C.. Intervirology. 2018;61(2):64-71",32,YR,,M,Y,,,20220317,,HP,PT,PT,EFAVIRENZ,Drug-induced liver injury;Hepatic fibrosis;Transaminases increased,154484334,LT,,,,,,,,,154484334,1,Hepatitis C
15835920,158359204,4,F,,20220304,20190117,20220317,EXP,,ZA-AUROBINDO-AUR-APL-2019-001256,AUROBINDO,,,,I,M,Y,4,KG,20220317,,MD,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Congenital umbilical hernia;Foetal exposure during pregnancy;Strabismus congenital,158359204,CA,,,158359204,1,20180208,,,,158359204,1,HIV infection
15836280,158362804,4,F,,20220304,20190117,20220317,EXP,,ZA-AUROBINDO-AUR-APL-2019-001293,AUROBINDO,,,,,M,Y,4,KG,20220317,,MD,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Strabismus congenital,158362804,CA,,,158362804,1,20180208,,,,158362804,1,HIV infection
15990442,159904422,2,F,,20220329,20190221,20220331,EXP,,FR-MYLANLABS-2019M1016125,MYLAN,"Pouga L, Santoro MM, Charpentier C, Di Carlo D, Romeo I, Artese A, et al. New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T). Chem-Biol-Drug-Des 2019;93(1):50-59.",35,YR,,F,Y,,,20220331,,HP,FR,FR,EFAVIRENZ,Pathogen resistance;Treatment failure,159904422,OT,,,,,,,,,159904422,1,HIV infection
15998853,159988538,8,F,,20220106,20190223,20220115,EXP,,CA-009507513-1902CAN006364,MERCK,unknown. unknown. unknown,52,YR,,M,Y,,,20220115,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Blood lactic acid increased;Diplopia;Dysphagia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,159988538,CA,,,159988538,1,,,91,DAY,159988538,1,HIV infection
16020890,1602089020,20,F,,20220223,20190301,20220309,EXP,,CA-AUROBINDO-AUR-APL-2019-010743,AUROBINDO,,54,YR,,M,Y,,,20220309,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,1602089020,HO,,,,,,,,,1602089020,1,HIV infection
16081155,160811559,9,F,,20220307,20190316,20220319,EXP,,CA-AUROBINDO-AUR-APL-2019-013363,AUROBINDO,,54,YR,,M,Y,,,20220319,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,160811559,OT,,,,,,,,,160811559,1,HIV infection
16340534,163405345,5,F,,20220308,20190522,20220322,EXP,,CA-AUROBINDO-AUR-APL-2019-027585,AUROBINDO,,54,YR,,M,Y,,,20220322,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,163405345,OT,,,,,,,,,163405345,1,HIV infection
16446145,1644614511,11,F,,20220323,20190618,20220329,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019GSK105240,VIIV,"Harris M, Larsen G, Montaner J.. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22 (14):1890-1892",54,YR,,M,Y,,,20220329,,HP,CA,CA,EFAVIRENZ,Drug interaction;Psychiatric decompensation,1644614511,OT,,,1644614511,6,20070620,,,,1644614511,1,Bipolar disorder
16446152,1644615211,11,F,,20220323,20190618,20220329,EXP,,CA-GLAXOSMITHKLINE-CA2019GSK105240,GLAXOSMITHKLINE,"Harris M, Larsen G, Montaner J.. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22 (14):1890-1892",54,YR,,M,Y,,,20220329,,HP,CA,CA,EFAVIRENZ,Drug interaction;Psychiatric decompensation,1644615211,OT,,,1644615211,6,20070620,,,,1644615211,1,Bipolar disorder
16549483,165494835,5,F,,20220120,20190710,20220203,EXP,,CA-AUROBINDO-AUR-APL-2019-037892,AUROBINDO,,54,YR,,M,Y,,,20220204,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,165494835,OT,,,,,,,,,165494835,1,Product used for unknown indication
16583628,165836284,4,F,,20220304,20190717,20220317,EXP,,PT-AUROBINDO-AUR-APL-2018-058733,AUROBINDO,"Soares J, Santos JV, Sarmento A, Costa-Pereira A. Spontaneous Viral Clearance in Sixteen HIV-Infected Patients with Chronic Hepatitis C. Intervirology. 2018;61(2):64-71",32,YR,,M,Y,,,20220317,,HP,PT,PT,EFAVIRENZ,Drug-induced liver injury;Hepatic fibrosis;Transaminases increased,165836284,OT,,,,,,,,,165836284,1,Chronic hepatitis C
16647369,166473695,5,F,20160425,20220224,20190730,20220301,EXP,,US-GILEAD-2019-0420236,GILEAD,,51,YR,A,M,Y,95.238,KG,20220301,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Chronic kidney disease;Dysuria;Economic problem;Emotional distress;End stage renal disease;Fatigue;Nephrolithiasis;Osteonecrosis;Pain;Renal failure;Tooth loss,166473695,OT,,,166473695,1,200608,201608,,,166473695,1,HIV infection
16676304,166763044,4,F,20080101,20220225,20190807,20220302,EXP,,US-GILEAD-2019-0421721,GILEAD,,46,YR,A,M,Y,81.633,KG,20220302,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone disorder;Bone loss;Depression;Economic problem;Emotional distress;Loss of personal independence in daily activities;Osteonecrosis;Osteoporosis;Pain;Renal failure;Sleep terror;Tooth loss;Upper limb fracture,166763044,OT,,,166763044,1,200912,201907,,,166763044,1,HIV infection
16826078,168260782,2,F,,20220111,20190919,20220120,EXP,,CA-AUROBINDO-AUR-APL-2019-059693,AUROBINDO,,44,YR,,M,Y,,,20220120,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,168260782,OT,,,168260782,9,,,355,DAY,168260782,1,Psychotic disorder
16834054,168340546,6,F,20080403,20220307,20190920,20220314,EXP,,US-GILEAD-2019-0428527,GILEAD,,69,YR,E,M,Y,86.183,KG,20220314,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Bone loss;Chronic kidney disease;Decreased appetite;Depression;Economic problem;Emotional distress;Facet joint syndrome;Fibula fracture;Hip arthroplasty;Intervertebral disc protrusion;Mobility decreased;Multiple fractures;Nephrosclerosis;Osteoarthritis;Osteonecrosis;Pain;Proteinuria;Radiculopathy;Renal failure;Renal tubular injury;Spinal osteoarthritis,168340546,OT,,,168340546,1,20040626,20190710,5492,DAY,168340546,1,HIV infection
16840694,168406945,5,F,20120628,20220112,20190923,20220120,EXP,,US-GILEAD-2019-0429308,GILEAD,,53,YR,A,M,Y,,,20220120,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Fatigue;Loss of personal independence in daily activities;Nephrogenic anaemia;Pain;Renal failure,168406945,OT,,,168406945,1,2004,201209,1615,DAY,168406945,1,HIV infection
16970346,169703467,7,F,20080101,20220214,20191029,20220217,EXP,,US-GILEAD-2019-0434731,GILEAD,,41,YR,A,F,Y,57.143,KG,20220217,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone density decreased;Depression;Economic problem;Emotional distress;Fanconi syndrome acquired;Fatigue;Glycosuria;Osteopenia;Osteoporosis;Pain;Pathological fracture;Proteinuria;Renal failure;Vitamin D decreased;Weight decreased,169703467,OT,,,169703467,1,2001,2010,3261,DAY,169703467,1,HIV infection
16974611,169746116,6,F,20060101,20220307,20191030,20220314,EXP,,US-GILEAD-2019-0434773,GILEAD,,56,YR,A,M,Y,,,20220314,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone density decreased;Depression;Economic problem;Emotional distress;Facet joint syndrome;Feeling abnormal;Gait disturbance;General physical health deterioration;Intervertebral disc degeneration;Intervertebral disc space narrowing;Lumbar vertebral fracture;Mobility decreased;Multiple fractures;Osteopenia;Osteoporosis;Pain;Partner stress;Sacroiliitis;Shoulder operation;Spinal compression fracture;Spinal osteoarthritis;Vertebral foraminal stenosis;Vertebroplasty,169746116,OT,,,169746116,1,2002,2015,,,169746116,1,HIV infection
17044956,170449566,6,F,,20220323,20191118,20220325,EXP,,CA-BAUSCH-BL-2019-058588,BAUSCH AND LOMB,"Harris M, Larsen G, Montaner J. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22 (14):1890-1892. doi:10.1097/QAD.0b013e32830e0169",54,YR,,M,Y,,,20220325,,HP,CA,CA,EFAVIRENZ,Drug interaction;Psychiatric decompensation,170449566,OT,,,,,,,,,170449566,1,Bipolar disorder
17075420,170754208,8,F,,20220106,20191126,20220111,EXP,,FR-MYLANLABS-2019M1114963,MYLAN,Gregorie M.. Drug-drug interaction in older patients living with HIV.. La letter de l^infectiologie. 2019;34(5):212-17,64,YR,,F,Y,,,20220111,,HP,FR,FR,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Cushing's syndrome;Drug interaction;Product administration error,170754208,HO,,,,,,,,,170754208,1,Asthma
17156913,171569137,7,F,20150101,20211223,20191216,20220105,EXP,,US-GILEAD-2019-0441951,GILEAD,,,,A,M,Y,104.31,KG,20220105,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Drug ineffective;Dysstasia;Economic problem;Emotional distress;Osteoporosis;Pain;Renal disorder;Renal failure,171569137,OT,,,171569137,1,2009,2017,,,171569137,1,HIV infection
17262061,172620613,3,F,20150115,20220215,20200113,20220221,EXP,,US-GILEAD-2020-0446121,GILEAD,,51,YR,A,M,Y,,,20220221,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Haematuria;Pain,172620613,OT,,,172620613,1,20070427,20170424,3650,DAY,172620613,1,HIV infection
17510565,175105657,7,F,20190114,20220202,20200306,20220210,EXP,,US-GILEAD-2020-0453649,GILEAD,,44,YR,A,M,Y,75.737,KG,20220210,,LW,US,US,SUSTIVA,Chronic kidney disease;Chronic kidney disease-mineral and bone disorder;Economic problem;Emotional distress;End stage renal disease;Hyperparathyroidism secondary;Pain;Renal failure,175105657,HO,,,175105657,1,20130920,20150501,588,DAY,175105657,1,HIV infection
17703788,177037885,5,F,20180401,20220122,20200424,20220128,EXP,,US-GILEAD-2020-0460165,GILEAD,,55,YR,A,M,Y,78.005,KG,20220128,,LW,US,US,SUSTIVA,Anxiety;Arthralgia;Blood creatinine increased;Bone density decreased;Bone loss;Chronic kidney disease;Depression;Dizziness;Economic problem;Emotional distress;Fracture;Nausea;Osteomalacia;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Pathological fracture;Renal tubular dysfunction,177037885,OT,,,177037885,2,2005,20190404,294,DAY,177037885,1,Product used for unknown indication
17705344,177053444,4,F,20090414,20220222,20200424,20220228,EXP,,US-GILEAD-2020-0460472,GILEAD,,48,YR,A,F,Y,58.97,KG,20220228,,LW,US,US,SUSTIVA,Bone density decreased;Depression;Emotional distress;Multiple fractures;Osteopenia;Osteoporosis;Pain;Upper limb fracture,177053444,OT,,,177053444,2,20070918,20121109,1879,DAY,177053444,1,Product used for unknown indication
17726107,177261074,4,F,20150401,20211229,20200429,20220105,EXP,,US-GILEAD-2020-0462425,GILEAD,,56,YR,A,M,Y,77.098,KG,20220105,,LW,US,US,SUSTIVA,Anxiety;Arthralgia;Bone density abnormal;Bone density decreased;Depression;Emotional distress;Multiple fractures;Osteopenia;Osteoporosis;Pain;Procedural pain;Road traffic accident;Tooth loss;Ulna fracture,177261074,OT,,,177261074,1,201108,201601,,,177261074,1,HIV infection
17771701,177717015,5,F,20090410,20220215,20200512,20220223,EXP,,US-GILEAD-2020-0465958,GILEAD,,32,YR,A,M,Y,,,20220222,,LW,US,US,SUSTIVA,Chronic kidney disease;Dental caries;Renal failure;Renal impairment;Renal injury;Skeletal injury;Tooth loss,177717015,OT,,,177717015,1,20090121,20160101,2536,DAY,177717015,1,HIV infection
17772651,177726514,4,F,20181001,20220324,20200512,20220330,EXP,,US-GILEAD-2020-0466109,GILEAD,,56,YR,A,F,Y,,,20220330,,LW,US,US,SUSTIVA,Ankle fracture;Bone density decreased;Bone loss;Multiple fractures;Osteonecrosis;Osteoporosis;Renal injury;Skeletal injury,177726514,OT,,,177726514,1,2004,2017,140,DAY,177726514,1,HIV infection
17799295,177992955,5,F,20120130,20220201,20200518,20220207,EXP,,US-GILEAD-2020-0467051,GILEAD,,44,YR,A,M,Y,90.703,KG,20220207,,LW,US,US,SUSTIVA,Acute kidney injury;Anxiety;Arthralgia;Back pain;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Hip arthroplasty;Intervertebral disc protrusion;Osteoarthritis;Pain;Renal cyst;Renal failure;Spinal deformity;Spinal osteoarthritis;Tendon disorder,177992955,OT,,,177992955,1,2009,2017,,,177992955,1,HIV infection
17917665,179176654,4,F,20120213,20220311,20200619,20220317,EXP,,US-GILEAD-2020-0473759,GILEAD,,60,YR,A,M,Y,76.19,KG,20220316,,LW,US,US,SUSTIVA,Bone density decreased;End stage renal disease;Fatigue;General physical health deterioration;Libido decreased;Medical diet;Nephrogenic anaemia;Nephropathy;Osteoporosis;Renal failure,179176654,OT,,,179176654,1,20031206,20040407,123,DAY,179176654,1,HIV infection
17930307,179303076,6,F,20100826,20220316,20200623,20220330,EXP,,US-GILEAD-2020-0474953,GILEAD,,49,YR,A,M,Y,97.5,KG,20220330,,LW,US,US,SUSTIVA,Anxiety;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Multiple fractures;Osteopenia;Osteoporosis;Pain;Rib fracture;Tooth fracture;Tooth loss;Upper limb fracture;Weight decreased,179303076,OT,,,179303076,1,2007,20110817,141,DAY,179303076,1,HIV infection
17960294,179602949,9,F,20180301,20220125,20200630,20220131,EXP,,US-GILEAD-2020-0476825,GILEAD,,49,YR,A,M,Y,68.027,KG,20220131,,LW,US,US,SUSTIVA,Bone density decreased;Dental necrosis;Emotional distress;Gait disturbance;Multiple fractures;Osteopenia;Osteoporosis;Pain;Radius fracture;Spinal compression fracture;Spinal fracture;Tooth fracture;Tooth loss;Ulna fracture,179602949,OT,,,179602949,1,2006,20190819,152,DAY,179602949,1,HIV infection
17963016,179630164,4,F,20090829,20220121,20200630,20220127,EXP,,US-GILEAD-2020-0477066,GILEAD,,50,YR,A,M,Y,68.027,KG,20220127,,LW,US,US,SUSTIVA,Acute kidney injury;Chronic kidney disease;End stage renal disease;Renal failure;Renal impairment,179630164,OT,,,179630164,1,20050308,20090322,1475,DAY,179630164,1,HIV infection
17985085,1798508510,10,F,,20220307,20200706,20220314,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2020EME116192,VIIV,,,,,M,Y,,,20220314,,HP,GB,GB,EFAVIRENZ,Feeling abnormal;Hospitalisation;Life expectancy shortened;Lung cancer metastatic;Lung neoplasm malignant;Malaise;Metastases to central nervous system,1798508510,OT,,,,,,,,,1798508510,1,Product used for unknown indication
17985108,1798510810,10,F,,20220307,20200706,20220314,EXP,,GB-GLAXOSMITHKLINE-GB2020EME116192,GLAXOSMITHKLINE,,,,,M,Y,,,20220314,,HP,GB,GB,EFAVIRENZ,Feeling abnormal;Hospitalisation;Life expectancy shortened;Lung cancer metastatic;Lung neoplasm malignant;Malaise;Metastases to central nervous system,1798510810,HO,,,,,,,,,1798510810,1,Product used for unknown indication
18007417,180074177,7,F,20120101,20220314,20200710,20220318,PER,,US-GILEAD-2020-0481205,GILEAD,,,,A,F,Y,54.422,KG,20220317,,LW,US,US,SUSTIVA,Anxiety;Bone density decreased;Chronic kidney disease;Depression;Drug dependence;Dysstasia;Emotional distress;Fanconi syndrome acquired;Femur fracture;Gait disturbance;Metabolic acidosis;Osteoporosis;Pain;Pancreatitis;Renal failure,180074177,HO,,,180074177,1,20080101,20080601,5,MON,180074177,1,HIV infection
18013641,180136418,8,F,20150717,20211222,20200713,20220215,PER,,US-GILEAD-2020-0481303,GILEAD,,53,YR,A,M,Y,90.703,KG,20220215,,LW,US,US,SUSTIVA,Bone density decreased;Chronic kidney disease;Emotional distress;Exercise tolerance decreased;Foot fracture;Lumbar vertebral fracture;Mobility decreased;Multiple fractures;Myelitis;Osteoarthritis;Osteoporosis;Pain;Rib fracture;Spinal osteoarthritis;Virologic failure,180136418,OT,,,180136418,1,20180108,20181012,277,DAY,180136418,1,HIV infection
18020729,180207294,4,F,20100101,20220131,20200714,20220207,EXP,,US-GILEAD-2020-0482670,GILEAD,,60,YR,A,M,Y,79.365,KG,20220207,,LW,US,US,SUSTIVA,Anxiety;Blood creatinine increased;Chronic kidney disease;Depression;Emotional distress;Gait disturbance;General physical health deterioration;Mobility decreased;Osteoporosis;Pain;Renal failure;Renal injury;Skeletal injury,180207294,OT,,,180207294,1,200503,201812,,,180207294,1,HIV infection
18022208,180222087,7,F,20200301,20220131,20200714,20220209,EXP,,US-TAKEDA-2020TUS018732,TAKEDA,,67,YR,,F,Y,57,KG,20220209,,CN,US,US,EFAVIRENZ,Alveolar lung disease;Blood cholesterol increased;Blood pressure increased;Cough;Diarrhoea;Hypersensitivity;Illness;Malaise;Nausea;Off label use;Photosensitivity reaction;Product dose omission issue;Rash;Skin burning sensation;Skin exfoliation;Vomiting,180222087,OT,,,180222087,1,20200325,20201016,206,DAY,180222087,1,Bone cancer
18022611,1802261116,16,F,,20220311,20200715,20220324,EXP,,GB-AUROBINDO-AUR-APL-2020-034425,AUROBINDO,,,,,M,Y,,,20220324,,HP,GB,GB,EFAVIRENZ,Feeling abnormal;Hospitalisation;Life expectancy shortened;Lung cancer metastatic;Lung neoplasm malignant;Malaise;Metastases to central nervous system,1802261116,HO,,,,,,,,,1802261116,1,Product used for unknown indication
18023506,180235065,5,F,20121001,20220114,20200715,20220119,EXP,,US-GILEAD-2020-0477191,GILEAD,,39,YR,A,M,Y,76.644,KG,20220119,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Emotional distress;End stage renal disease;General physical health deterioration;Pain;Renal injury;Tooth loss,180235065,OT,,,180235065,1,200801,201401,,,180235065,1,HIV infection
18057020,180570203,3,F,20090212,20220127,20200722,20220202,EXP,,US-GILEAD-2020-0484454,GILEAD,,33,YR,A,M,Y,88.435,KG,20220202,,LW,US,US,SUSTIVA,Abnormal dreams;Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Decreased activity;Emotional distress;Fatigue;Glomerular filtration rate decreased;Loss of personal independence in daily activities;Pain;Quality of life decreased;Renal disorder;Renal failure;Renal impairment,180570203,OT,,,180570203,1,20040120,20050519,485,DAY,180570203,1,HIV infection
18096248,180962484,4,F,20140101,20211222,20200730,20220105,PER,,US-GILEAD-2020-0487166,GILEAD,,56,YR,A,M,Y,113.39,KG,20220105,,LW,US,US,SUSTIVA,Acute kidney injury;Emotional distress;Fanconi syndrome acquired;Pain;Proteinuria;Renal impairment,180962484,OT,,,180962484,1,20070227,20170919,3857,DAY,180962484,1,HIV infection
18114349,181143496,6,F,20120101,20220310,20200805,20220315,EXP,,US-GILEAD-2020-0488911,GILEAD,,,,A,M,Y,83.447,KG,20220314,,LW,US,US,SUSTIVA,Bone density decreased;Bone loss;Chronic kidney disease;Emotional distress;Osteoarthritis;Osteonecrosis;Pain;Polyneuropathy;Renal cyst;Renal failure;Tooth loss;Vitamin D deficiency,181143496,OT,,,181143496,1,20000101,201803,7304,DAY,181143496,1,HIV infection
18120238,181202384,4,F,20090401,20220303,20200806,20220309,EXP,,US-GILEAD-2020-0484417,GILEAD,,74,YR,E,M,Y,90.718,KG,20220309,,LW,US,US,SUSTIVA,Abdominal pain;Back pain;Bone density decreased;Chronic kidney disease;Emotional distress;Gait disturbance;Nausea;Nephropathy;Osteopenia;Pain;Renal cyst;Renal failure;Renal impairment,181202384,OT,,,181202384,1,2001,2001,72,DAY,181202384,1,HIV infection
18179409,181794098,8,F,,20220111,20200821,20220121,EXP,,CA-ROCHE-2583896,ROCHE,,52,YR,,M,Y,,,20220121,,HP,CA,,EFAVIRENZ;SUSTIVA,Blood lactic acid increased;Diplopia;Dysphagia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,181794098,OT,,,,,,,,,181794098,1,HIV infection
18224609,182246096,6,F,20060101,20220124,20200902,20220204,EXP,,US-GILEAD-2020-0492507,GILEAD,,56,YR,A,M,Y,77.098,KG,20220204,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Asthenia;Back pain;Chronic kidney disease;Depression;Dysstasia;Emotional distress;End stage renal disease;Gait disturbance;Hyperkalaemia;Osteonecrosis;Pain;Renal failure;Tooth loss,182246096,HO,,,182246096,1,20051007,20060913,341,DAY,182246096,1,HIV infection
18344183,183441835,5,F,20180604,20220121,20201005,20220202,EXP,,JP-JNJFOC-A-CH2019-192680,JOHNSON AND JOHNSON,,56,YR,A,M,Y,48.9,KG,20220202,,MD,JP,JP,EFAVIRENZ,Brain natriuretic peptide increased;Disease progression;Hypoxia;Oxygen saturation decreased;Pulmonary arterial hypertension,183441835,HO,,,183441835,1,20180521,20180603,743,DAY,183441835,1,Pulmonary arterial hypertension
18349036,183490365,5,F,,20220323,20201006,20220330,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK189276,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20220330,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,183490365,OT,,,,,,,,,183490365,1,HIV infection
18349038,183490385,5,F,,20220323,20201006,20220330,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2018GSK189276,VIIV,,54,YR,,M,Y,,,20220330,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,183490385,OT,,,,,,,,,183490385,1,HIV infection
18387262,183872624,4,F,20160401,20211203,20201015,20220106,EXP,,US-GILEAD-2020-0498473,GILEAD,,47,YR,A,M,Y,,,20220106,,LW,US,US,SUSTIVA,Bone density decreased;Osteopenia;Osteoporosis;Spinal disorder;Spinal stenosis;Tooth loss,183872624,OT,,,183872624,1,2006,2016,,,183872624,1,HIV infection
18487650,184876507,7,F,20201027,20220317,20201111,20220321,EXP,,CN-GILEAD-2020-0503255,GILEAD,,,,A,M,Y,80,KG,20220321,,HP,CN,CN,TENOFOVIR DISOPROXIL FUMARATE/LAMIVUDINE/EFAVIRENZ,Pneumonia,184876507,OT,,,184876507,1,20201014,20201027,13,DAY,184876507,1,HIV infection
18517808,185178083,3,F,20120120,20220131,20201118,20220207,PER,,US-GILEAD-2020-0503385,GILEAD,,38,YR,A,M,Y,77.098,KG,20220207,,LW,US,US,SUSTIVA,Blood creatinine increased;Nephropathy;Renal cyst;Renal failure,185178083,OT,,,185178083,1,2004,2016,1945,DAY,185178083,1,HIV infection
18870387,188703876,6,F,20201231,20220121,20210209,20220126,EXP,,CN-GILEAD-2021-0515844,GILEAD,,,,A,M,Y,62,KG,20220126,,HP,CN,CN,TENOFOVIR DISOPROXIL FUMARATE/LAMIVUDINE/EFAVIRENZ,Liver injury;Opportunistic infection,188703876,HO,,,188703876,1,20201229,20210112,14,DAY,188703876,1,HIV infection
18893076,188930766,6,F,,20220110,20210215,20220113,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013005,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20220113,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,188930766,DE,,,,,,,,,188930766,1,HIV infection
18924449,189244494,4,F,,20220110,20210222,20220121,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013816,BRISTOL MYERS SQUIBB,,44,YR,,M,Y,,,20220121,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,189244494,HO,,,,,,,,,189244494,1,HIV infection
18925910,189259104,4,F,,20220120,20210222,20220203,EXP,,CA-AUROBINDO-AUR-APL-2021-006678,AUROBINDO,,54,YR,,M,Y,,,20220204,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,189259104,DE,,,,,,,,,189259104,1,HIV infection
18930094,189300943,3,F,,20220126,20210223,20220131,EXP,,CA-BAUSCH-BL-2021-005970,BAUSCH AND LOMB,,54,YR,,M,Y,,,20220131,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189300943,OT,,,,,,,,,189300943,1,Bipolar disorder
18930120,189301202,2,F,,20220126,20210223,20220201,EXP,,CA-BAUSCH-BL-2021-006015,BAUSCH AND LOMB,,54,YR,,M,Y,,,20220201,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,189301202,OT,,,,,,,,,189301202,1,Product used for unknown indication
18954100,189541002,2,F,,20220126,20210301,20220202,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK053499,VIIV,,54,YR,,M,Y,,,20220202,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,189541002,OT,,,,,,,,,189541002,1,Product used for unknown indication
18954111,189541112,2,F,,20220126,20210301,20220202,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK053499,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20220202,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,189541112,OT,,,,,,,,,189541112,1,Product used for unknown indication
18958430,189584304,4,F,,20220223,20210302,20220302,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK053512,VIIV,,54,YR,,M,Y,,,20220302,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,189584304,OT,,,,,,,,,189584304,1,Bipolar disorder
18958433,189584334,4,F,,20220223,20210302,20220302,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK053512,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20220302,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,189584334,OT,,,,,,,,,189584334,1,Bipolar disorder
18962597,189625973,3,F,,20220126,20210303,20220202,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK053501,VIIV,,54,YR,,M,Y,,,20220202,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189625973,OT,,,,,,,,,189625973,1,Bipolar disorder
18962619,189626193,3,F,,20220126,20210303,20220202,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK053501,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20220202,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189626193,OT,,,,,,,,,189626193,1,Bipolar disorder
18999142,189991422,2,F,,20220307,20210311,20220315,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-023102,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20220315,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue,189991422,OT,,,,,,,,,189991422,1,Product used for unknown indication
19034557,190345573,3,F,,20211222,20210319,20220101,EXP,,CZ-009507513-2103CZE003413,MERCK,"Fleischhans L, Jilich D, Machala L.. A Multidrug-resistant Form Of HIV Infection - A Hopeless Story With A Hopeful Ending.. Acta medicinae. 2021;10(14):50-2",53,YR,,M,Y,,,20220101,,MD,CZ,CZ,EFAVIRENZ,Drug ineffective;Dyslipidaemia;Glucose tolerance impaired;Hypertension,,,,,190345573,1,20090507,20061016,434,DAY,190345573,4,HIV infection
19089720,190897202,2,F,,20220125,20210403,20220201,EXP,,CA-ROCHE-2802838,ROCHE,,54,YR,,M,Y,,,20220201,,HP,CA,,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,190897202,OT,,,,,,,,,190897202,1,Bipolar disorder
19134529,191345294,4,F,,20220323,20210414,20220330,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK079642,VIIV,,54,YR,,M,Y,,,20220330,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities;Off label use,191345294,OT,,,,,,,,,191345294,1,Bipolar disorder
19134538,191345384,4,F,,20220323,20210414,20220330,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK079642,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20220330,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities;Off label use,191345384,OT,,,,,,,,,191345384,1,Bipolar disorder
19182539,191825392,2,F,,20220304,20210427,20220318,EXP,,RO-AUROBINDO-AUR-APL-2020-012807,AUROBINDO,,31,YR,,M,Y,,,20220318,,MD,RO,RO,EFAVIRENZ,Drug ineffective;Virologic failure,191825392,OT,,,,,,,,,191825392,1,HIV infection
19225328,192253283,3,F,,20220307,20210506,20220315,EXP,,CA-ROCHE-2822133,ROCHE,,54,YR,,M,Y,,,20220315,,HP,CA,,SUSTIVA,Depression;Drug interaction,192253283,HO,,,,,,,,,192253283,1,Bipolar disorder
19370072,193700722,2,F,20100601,20220208,20210603,20220216,EXP,,US-GILEAD-2021-0534078,GILEAD,,46,YR,A,M,Y,123.36,KG,20220215,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Pain;Renal failure,193700722,OT,,,193700722,1,2009,2016,,,193700722,1,HIV infection
19374072,193740722,2,F,20040101,20220216,20210603,20220221,EXP,,US-GILEAD-2021-0534101,GILEAD,,,,A,M,Y,79.365,KG,20220221,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asocial behaviour;Asthenia;Chronic kidney disease;Decreased activity;Depression;Emotional distress;Mood swings;Musculoskeletal disorder;Pain;Pollakiuria,193740722,OT,,,193740722,1,2004,2015,,,193740722,1,HIV infection
19392273,193922733,3,F,20111201,20220303,20210608,20220311,EXP,,US-GILEAD-2021-0534892,GILEAD,,55,YR,A,M,Y,108.84,KG,20220311,,LW,US,US,SUSTIVA,Acute kidney injury;Anaemia;Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Fatigue;Gait disturbance;Nightmare;Pain,193922733,OT,,,193922733,1,2005,201512,,,193922733,1,HIV infection
19394148,193941482,2,F,20200401,20220119,20210609,20220125,EXP,,US-GILEAD-2021-0534824,GILEAD,,57,YR,A,M,Y,,,20220125,,LW,US,US,SUSTIVA,Adverse event;Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Dysstasia;Emotional distress;Gait disturbance;Osteoarthritis;Osteoporosis;Pain,193941482,OT,,,193941482,1,2001,2018,,,193941482,1,HIV infection
19394276,193942762,2,F,20070101,20220119,20210609,20220125,EXP,,US-GILEAD-2021-0534828,GILEAD,,,,A,M,Y,88.435,KG,20220125,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood urine present;Bone density decreased;Bone disorder;Chronic kidney disease;Dysstasia;Dysuria;Emotional distress;Gait disturbance;General physical health deterioration;Hand fracture;Hip fracture;Nephrolithiasis;Osteopenia;Osteoporosis;Pain;Post-traumatic stress disorder;Renal injury,193942762,OT,,,193942762,1,2004,2004,,,193942762,1,HIV infection
19397632,193976323,3,F,20110501,20220209,20210610,20220324,EXP,,US-GILEAD-2021-0534867,GILEAD,,59,YR,A,M,Y,78.005,KG,20220324,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Bone density decreased;Emotional distress;Fall;Osteopenia;Osteoporosis;Pain;Rib fracture;Spinal compression fracture,193976323,OT,,,193976323,1,200802,201801,,,193976323,1,HIV infection
19398179,193981792,2,F,20171201,20220218,20210610,20220224,EXP,,US-GILEAD-2021-0534890,GILEAD,,54,YR,A,M,Y,63.492,KG,20220224,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Hip fracture;Mobility decreased;Osteoporosis;Pain;Vitamin D deficiency,193981792,OT,,,193981792,1,2010,2004,,,193981792,1,HIV infection
19406148,194061484,4,F,20160101,20220304,20210611,20220315,EXP,,LV-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-054655,BRISTOL MYERS SQUIBB,,41,YR,,M,Y,,,20220315,,CN,LV,LV,EFAVIRENZ,Blood cholesterol abnormal;Blood triglycerides abnormal;Coronary artery disease;Dizziness;High density lipoprotein abnormal;Hyperhidrosis;Hyperlipidaemia;Low density lipoprotein abnormal;Nightmare;Pulmonary hypertension,194061484,OT,,,194061484,1,2015,2016,,,194061484,1,HIV infection
19430373,194303734,4,F,20100924,20211123,20210617,20220128,PER,,US-GILEAD-2021-0536679,GILEAD,,47,YR,A,M,Y,,,20220128,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Death;Emotional distress;Pain;Renal failure,194303734,OT,,,194303734,1,2010,20101024,,,194303734,1,HIV infection
19435753,194357532,2,F,20190601,20220221,20210618,20220224,EXP,,US-GILEAD-2021-0536647,GILEAD,,65,YR,E,M,Y,81.646,KG,20220224,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Decreased activity;Emotional distress;Osteopenia;Osteoporosis;Pain,194357532,OT,,,194357532,1,200503,200505,,,194357532,1,HIV infection
19445667,194456672,2,F,20160101,20220222,20210622,20220225,EXP,,LV-VIIV HEALTHCARE LIMITED-LV2021EME131017,VIIV,,57,YR,,M,Y,,,20220225,,MD,LV,LV,EFAVIRENZ,Depression;Disease recurrence;Neurosyphilis,194456672,OT,,,194456672,1,2016,202009,,,194456672,1,HIV infection
19445668,194456682,2,F,,20220223,20210622,20220302,EXP,,LV-VIIV HEALTHCARE LIMITED-LV2021EME131019,VIIV,,41,YR,,M,Y,,,20220302,,MD,LV,LV,EFAVIRENZ,Dizziness;Hyperlipidaemia;Nightmare;Pulmonary hypertension,194456682,OT,,,194456682,1,2018,2020,,,194456682,1,HIV infection
19445690,194456902,2,F,,20220223,20210622,20220302,EXP,,LV-GLAXOSMITHKLINE-LV2021EME131019,GLAXOSMITHKLINE,,41,YR,,M,Y,,,20220302,,MD,LV,LV,EFAVIRENZ,Dizziness;Hyperlipidaemia;Nightmare;Pulmonary hypertension,194456902,OT,,,194456902,1,2018,2020,,,194456902,1,HIV infection
19445706,194457062,2,F,20160101,20220222,20210622,20220225,EXP,,LV-GLAXOSMITHKLINE-LV2021EME131017,GLAXOSMITHKLINE,,57,YR,,M,Y,,,20220225,,MD,LV,LV,EFAVIRENZ,Depression;Disease recurrence;Neurosyphilis,194457062,OT,,,194457062,1,2016,202009,,,194457062,1,HIV infection
19455864,194558642,2,F,20080501,20220110,20210624,20220118,EXP,,US-GILEAD-2021-0537463,GILEAD,,41,YR,A,M,Y,100.69,KG,20220118,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;End stage renal disease;Hyperparathyroidism secondary;Nephrogenic anaemia;Pain;Renal failure,194558642,OT,,,194558642,1,2006,200810,,,194558642,1,HIV infection
19455876,194558762,2,F,20140101,20220121,20210624,20220201,EXP,,US-GILEAD-2021-0537450,GILEAD,,,,A,M,Y,79.4,KG,20220201,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Arthralgia;Bone density decreased;Dysstasia;Emotional distress;Gait disturbance;Hand fracture;Pain,194558762,OT,,,194558762,1,2009,201312,,,194558762,1,HIV infection
19457453,194574532,2,F,20140101,20220131,20210624,20220208,EXP,,US-GILEAD-2021-0537381,GILEAD,,,,,F,Y,127,KG,20220208,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Arthralgia;Arthritis;Bone density decreased;Dysstasia;Emotional distress;Foot fracture;Gait disturbance;Osteoporosis;Pain;Pain in extremity,194574532,OT,,,194574532,1,2001,2016,,,194574532,1,HIV infection
19457492,194574922,2,F,20170301,20220304,20210624,20220308,EXP,,US-GILEAD-2021-0537546,GILEAD,,41,YR,A,M,Y,88.435,KG,20220308,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Depression;Emotional distress;Glomerular filtration rate decreased;Hypersensitivity;Pain;Renal impairment,194574922,OT,,,194574922,1,2012,201708,,,194574922,1,HIV infection
19462437,194624372,2,F,20110101,20220324,20210625,20220331,EXP,,US-GILEAD-2021-0537930,GILEAD,,,,A,M,Y,88.435,KG,20220331,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Mobility decreased;Multiple fractures;Osteoporosis;Pain,194624372,OT,,,194624372,1,2008,201903,,,194624372,1,HIV infection
19465462,194654622,2,F,,20220124,20210624,20220204,EXP,,US-GILEAD-2021-0537436,GILEAD,,,,A,M,Y,83.9,KG,20220204,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Atrial fibrillation;Blood creatinine increased;Blood lactic acid increased;Depression;Dizziness;Dyspnoea;Emotional distress;Hypertension;Insomnia;Muscle fatigue;Muscle spasms;Pain;Palpitations;Pollakiuria;Renal injury;Swelling,194654622,OT,,,194654622,1,2007,2018,,,194654622,1,HIV infection
19465512,194655122,2,F,20120101,20220112,20210624,20220120,EXP,,US-GILEAD-2021-0537424,GILEAD,,,,A,F,Y,99.33,KG,20220120,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Gait disturbance;Hypertension;Pain;Patella fracture;Renal injury;Rib fracture;Schizophrenia;Spinal fracture,194655122,OT,,,194655122,1,2009,2016,,,194655122,1,HIV infection
19469199,194691992,2,F,20160101,20220228,20210628,20220310,EXP,,LV-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-062115,BRISTOL MYERS SQUIBB,,57,YR,,M,Y,,,20220310,,CN,LV,LV,EFAVIRENZ,Depression;Disease recurrence;Neurosyphilis,194691992,OT,,,194691992,1,2016,,,,194691992,1,HIV infection
19502163,195021633,3,F,20080527,20220222,20210707,20220225,EXP,,US-GILEAD-2021-0539466,GILEAD,,27,YR,A,M,Y,72.562,KG,20220225,,LW,US,US,SUSTIVA,Acute kidney injury;Anaemia;Anhedonia;Anxiety;Asthenia;Chronic kidney disease;Emotional distress;Fatigue;Osteopenia;Pain;Renal impairment;Urinary tract infection,195021633,HO,,,195021633,1,20040629,20060425,665,DAY,195021633,1,HIV infection
19504053,195040532,2,F,20120101,20220217,20210707,20220223,EXP,,US-GILEAD-2021-0539504,GILEAD,,,,A,F,Y,74.84,KG,20220223,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Asthenia;Back pain;Chills;Chronic kidney disease;Depression;Dyspnoea exertional;Emotional distress;Insomnia;Mobility decreased;Pain;Pollakiuria;Pruritus,195040532,OT,,,195040532,1,2004,201610,,,195040532,1,HIV infection
19504686,195046862,2,F,20010101,20220118,20210707,20220125,EXP,,US-GILEAD-2021-0539470,GILEAD,,,,A,F,Y,68.027,KG,20220125,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Bone density decreased;Chronic kidney disease;Decreased appetite;Depression;Emotional distress;End stage renal disease;Fatigue;Hyperphosphataemia;Mobility decreased;Pain;Renal injury;Stress,195046862,OT,,,195046862,1,2001,201307,,,195046862,1,HIV infection
19516890,195168903,3,F,20050101,20220216,20210711,20220221,PER,,US-GILEAD-2021-0539492,GILEAD,,,,A,M,Y,83.914,KG,20220221,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Decreased activity;Decreased interest;Depressed mood;Emotional distress;Multiple fractures;Pain;Stress;Tibia fracture,195168903,OT,,,195168903,1,2008,201908,,,195168903,1,HIV infection
19593176,195931762,2,F,,20220208,20210722,20220216,PER,,US-GILEAD-2021-0541373,GILEAD,,,,A,M,Y,113.39,KG,20220216,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Depression;Emotional distress;Pain;Renal failure,195931762,OT,,,195931762,1,2002,2004,,,195931762,1,HIV infection
19605568,196055683,3,F,20071001,20220112,20210723,20220120,PER,,US-GILEAD-2021-0541721,GILEAD,,43,YR,A,M,Y,,,20220120,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Emotional distress;Fatigue;Hypertension;Pain;Pollakiuria;Protein total abnormal;Renal impairment,196055683,OT,,,196055683,1,2008,20090219,493,DAY,196055683,1,HIV infection
19608297,196082972,2,F,,20220223,20210726,20220228,EXP,,CA-BAUSCH-BL-2021-025928,BAUSCH AND LOMB,,54,YR,,M,Y,,,20220228,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,196082972,OT,,,,,,,,,196082972,1,Bipolar disorder
19609605,196096053,3,F,,20220323,20210726,20220325,EXP,,CA-BAUSCH-BL-2021-025913,BAUSCH AND LOMB,,54,YR,,M,Y,,,20220325,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities;Off label use,196096053,OT,,,,,,,,,196096053,1,Bipolar disorder
19610462,196104622,2,F,20060601,20220117,20210726,20220124,EXP,,US-GILEAD-2021-0541777,GILEAD,,52,YR,A,M,Y,180,KG,20220124,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Pain;Renal impairment,196104622,OT,,,196104622,1,20061009,20091204,1152,DAY,196104622,1,HIV infection
19640051,196400513,3,F,20050101,20220217,20210730,20220221,EXP,,US-GILEAD-2021-0542435,GILEAD,,,,A,F,Y,81.633,KG,20220221,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone pain;Emotional distress;Exercise tolerance decreased;Gait disturbance;Muscular weakness;Osteoporosis;Pain;Renal impairment,196400513,OT,,,196400513,1,2002,2008,,,196400513,1,HIV infection
19644204,196442043,3,F,20160414,20220122,20210801,20220128,PER,,US-GILEAD-2021-0542305,GILEAD,,59,YR,A,M,Y,83.447,KG,20220128,,LW,US,US,SUSTIVA,Acute kidney injury;Anaemia;Anhedonia;Anxiety;Asthenia;Chronic kidney disease;Emotional distress;Metabolic acidosis;Nausea;Nocturia;Pain;Sleep disorder;Urinary hesitation;Vomiting,196442043,HO,,,196442043,1,2016,201901,30,DAY,196442043,1,HIV infection
19648776,196487763,3,F,20130101,20220125,20210803,20220131,PER,,US-GILEAD-2021-0542370,GILEAD,,,,A,M,Y,94.331,KG,20220131,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bipolar disorder;Blood urine present;Chronic kidney disease;Decreased appetite;Dysuria;Emotional distress;Pain;Renal impairment;T-lymphocyte count increased;Therapeutic product effect decreased,196487763,OT,,,196487763,1,2012,2015,,,196487763,1,HIV infection
19649170,196491702,2,F,20180801,20220208,20210802,20220217,EXP,,US-GILEAD-2021-0542324,GILEAD,,49,YR,A,M,Y,151.95,KG,20220217,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Decreased activity;Emotional distress;Foot fracture;Osteopenia;Osteoporosis;Pain,196491702,OT,,,196491702,1,2011,201307,,,196491702,1,HIV infection
19654378,196543782,2,F,20080101,20220207,20210804,20220214,EXP,,US-GILEAD-2021-0542326,GILEAD,,,,A,M,Y,,,20220214,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Gout;Hypertension;Mobility decreased;Pain;Pneumonia;Seizure,196543782,OT,,,196543782,1,2001,201608,,,196543782,1,HIV infection
19654911,196549112,2,F,20100101,20220125,20210804,20220201,EXP,,US-GILEAD-2021-0542389,GILEAD,,,,A,F,Y,90.703,KG,20220201,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Emotional distress;Gait disturbance;Impaired work ability;Osteoporosis;Pain;Protein urine present;Renal cyst;Renal impairment;Sitting disability,196549112,OT,,,196549112,1,2009,,,,196549112,1,HIV infection
19656612,196566122,2,F,20040101,20220210,20210804,20220216,EXP,,US-GILEAD-2021-0542302,GILEAD,,40,YR,A,M,Y,81.633,KG,20220216,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Chronic kidney disease;Depression;Emotional distress;Fractured sacrum;Mood swings;Osteoporosis;Pain;Pollakiuria;Psychiatric symptom;Renal failure;Renal impairment,196566122,OT,,,196566122,1,2001,2004,,,196566122,1,HIV infection
19658691,196586912,2,F,20180309,20220215,20210804,20220221,EXP,,US-GILEAD-2021-0542308,GILEAD,,57,YR,A,M,Y,90.703,KG,20220221,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Asthenia;Chronic kidney disease;Emotional distress;Pain,196586912,OT,,,196586912,1,2014,201803,,,196586912,1,HIV infection
19660115,196601152,2,F,20120401,20220116,20210805,20220121,EXP,,US-GILEAD-2021-0542448,GILEAD,,54,YR,A,M,Y,,,20220121,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Loss of personal independence in daily activities;Multiple fractures;Osteoporosis;Pain,196601152,OT,,,196601152,1,2006,201204,,,196601152,1,HIV infection
19660525,196605252,2,F,20130101,20220105,20210805,20220112,EXP,,US-GILEAD-2021-0542310,GILEAD,,71,YR,E,M,Y,,,20220112,,LW,US,US,SUSTIVA,Acute kidney injury;Anaemia;Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Emotional distress;Fanconi syndrome acquired;Gastrointestinal haemorrhage;Hyperkalaemia;Loss of personal independence in daily activities;Pain,196605252,OT,,,196605252,1,2005,20150821,,,196605252,1,HIV infection
19691781,196917812,2,F,,20211230,20210812,20220103,EXP,,CA-AstraZeneca-2021A673857,ASTRAZENECA,,54,YR,,M,Y,,,20220103,,MD,CA,,SUSTIVA,Depression;Drug interaction,196917812,DE,,,,,,,,,196917812,1,Bipolar disorder
19701763,197017632,2,F,,20220113,20210813,20220118,EXP,,CA-ROCHE-2884211,ROCHE,,54,YR,,M,Y,,,20220118,,HP,CA,,SUSTIVA,Depression;Drug interaction,197017632,OT,,,,,,,,,197017632,1,Bipolar disorder
19711977,197119773,3,F,,20220110,20210816,20220124,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-079033,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20220124,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,197119773,OT,,,,,,,,,197119773,1,HIV infection
19714509,197145096,6,F,,20220117,20210818,20220125,EXP,,CA-JNJFOC-20210821624,JOHNSON AND JOHNSON,,40,YR,A,F,Y,,,20220125,,CN,CA,CA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Bacillus infection;Bacterial vulvovaginitis;Cataract;Cellulitis;Central obesity;Colitis ulcerative;Cushingoid;Drug ineffective;Escherichia infection;Furuncle;Therapy non-responder;Weight increased,197145096,OT,,,197145096,1,,,7,MON,197145096,1,Colitis ulcerative
19714944,197149442,2,F,20130101,20220304,20210818,20220309,PER,,US-GILEAD-2021-0544301,GILEAD,,,,A,F,Y,,,20220309,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Emotional distress;Pain;Renal failure;Renal impairment,197149442,DE,,,197149442,1,2006,201812,,,197149442,1,HIV infection
19716722,197167223,3,F,20180101,20220209,20210819,20220217,PER,,US-GILEAD-2021-0544308,GILEAD,,,,A,F,Y,70.748,KG,20220216,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Dysuria;Emotional distress;Pain;Renal failure;Urinary retention,197167223,OT,,,197167223,1,2013,2019,,,197167223,1,HIV infection
19724690,197246902,2,F,20050101,20220302,20210820,20220304,PER,,US-GILEAD-2021-0544464,GILEAD,,,,A,M,Y,92.986,KG,20220304,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Depression;Emotional distress;Loss of personal independence in daily activities;Lower limb fracture;Osteopenia;Pain;Renal failure;Renal impairment,197246902,OT,,,197246902,1,2004,2017,,,197246902,1,HIV infection
19725824,197258242,2,F,20131001,20220301,20210820,20220304,EXP,,US-GILEAD-2021-0544326,GILEAD,,51,YR,A,M,Y,95.057,KG,20220304,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Bone density decreased;Depression;Emotional distress;Gait disturbance;Multiple fractures;Osteopenia;Pain;Rib fracture,197258242,OT,,,197258242,1,2005,201805,,,197258242,1,HIV infection
19749484,197494843,3,F,20181214,20211230,20210826,20220104,EXP,,CZ-MYLANLABS-2021M1053292,MYLAN,"Fleischhans L, Jilich D, Machala L.. A Multidrug-resistant Form Of HIV Infection A Hopeless Story With A Hopeful Ending.. Acta medicinae. 2021;10(14):50-52",6,DEC,,M,Y,,,20220104,,MD,CZ,CZ,EFAVIRENZ,Drug ineffective;Dyslipidaemia;Dysuria;Glucose tolerance impaired;HIV infection;Hypertension;Immunodeficiency;Kaposi's sarcoma;Laboratory test abnormal;Lymphoedema;Multiple-drug resistance;Neoplasm progression;Pancytopenia;Pyrexia;Skin lesion;Superinfection bacterial;Toxicity to various agents;Urinary tract infection;Virologic failure,197494843,HO,,,197494843,1,2021,202107,434,DAY,197494843,1,Kaposi's sarcoma
19755862,197558623,3,F,,20211222,20210827,20220106,EXP,,CA-ALVOGEN-2021-ALVOGEN-117376,ALVOGEN,,44,YR,,M,Y,,,20220106,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,197558623,HO,,,197558623,1,20070729,,,,197558623,1,Depression
19764262,197642622,2,F,20100101,20220118,20210830,20220124,PER,,US-GILEAD-2021-0545395,GILEAD,,,,A,M,Y,98.413,KG,20220124,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Emotional distress;Pain;Pollakiuria;Proteinuria;Renal impairment;Sleep disorder,,,,,197642622,1,2001,201010,,,197642622,1,HIV infection
19766166,197661663,3,F,20150101,20220303,20210831,20220308,EXP,,US-GILEAD-2021-0545320,GILEAD,,,,A,F,Y,58.957,KG,20220308,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Arthropathy;Asthenia;Body height decreased;Bone density decreased;Bone pain;Emotional distress;Fatigue;General physical health deterioration;Genotype drug resistance test positive;Mobility decreased;Osteopenia;Osteoporosis;Pain,197661663,OT,,,197661663,1,2007,20200901,2567,DAY,197661663,1,HIV infection
19777748,197777482,2,F,,20220104,20210902,20220117,EXP,,CA-ALVOGEN-2021-ALVOGEN-117410,ALVOGEN,,54,YR,,M,Y,,,20220117,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction,197777482,OT,,,,,,,,,197777482,1,Bipolar disorder
19795983,197959832,2,F,20100501,20211221,20210907,20220104,EXP,,US-GILEAD-2021-0547308,GILEAD,,55,YR,A,F,Y,105.67,KG,20220104,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Mobility decreased;Osteopenia;Pain;Wrist fracture,197959832,OT,,,197959832,1,2003,2008,,,197959832,1,HIV infection
19809327,198093272,2,F,20100301,20220201,20210909,20220208,EXP,,US-GILEAD-2021-0547292,GILEAD,,44,YR,A,M,Y,80.272,KG,20220208,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Bone density decreased;Bone pain;Depression;Emotional distress;Osteoporosis;Pain,198093272,OT,,,198093272,1,2001,2004,,,198093272,1,HIV infection
19812559,198125592,2,F,20060101,20220307,20210910,20220314,PER,,US-GILEAD-2021-0547303,GILEAD,,,,A,F,Y,73.469,KG,20220314,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Emotional distress;Osteopenia;Pain,,,,,198125592,1,2004,201607,,,198125592,1,HIV infection
19823132,198231323,3,F,20150701,20220307,20210913,20220310,PER,,US-GILEAD-2021-0547356,GILEAD,,53,YR,A,M,Y,75.737,KG,20220310,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Compression fracture;Emotional distress;Gait disturbance;Mobility decreased;Multiple fractures;Osteopenia;Pain,198231323,OT,,,198231323,1,2010,201701,,,198231323,1,HIV infection
19840985,198409852,2,F,,20220314,20210916,20220317,EXP,,CA-AstraZeneca-2021A724489,ASTRAZENECA,,54,YR,,M,Y,,,20220317,,MD,CA,,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,198409852,DE,,,,,,,,,198409852,1,Bipolar disorder
19844479,198444792,2,F,,20220204,20210916,20220207,EXP,,CA-AstraZeneca-2021A724480,ASTRAZENECA,,54,YR,,M,Y,,,20220207,,MD,CA,,SUSTIVA,Depression;Drug interaction,198444792,DE,,,,,,,,,198444792,1,Bipolar disorder
19855115,198551153,3,F,20070101,20211203,20210920,20220107,EXP,,US-GILEAD-2021-0548468,GILEAD,,,,A,M,Y,,,20220107,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Dysstasia;Emotional distress;Exercise tolerance decreased;Pain;Renal injury;Skeletal injury,198551153,OT,,,198551153,1,2003,2011,,,198551153,1,HIV infection
19855618,198556182,2,F,20170101,20220112,20210920,20220120,EXP,,US-GILEAD-2021-0548487,GILEAD,,,,A,M,Y,,,20220120,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Emotional distress;Osteoporosis;Pain;Rib fracture,198556182,OT,,,198556182,1,2006,2019,,,198556182,1,HIV infection
19856526,198565262,2,F,,20220118,20210920,20220128,EXP,,CA-APOTEX-2021AP042592,APOTEX,,10,YR,,F,Y,,,20220128,,HP,CA,CA,EFAVIRENZ,Chills;Disease recurrence;Nephropathy toxic,198565262,OT,,,198565262,4,,,4,WK,198565262,1,Drug toxicity prophylaxis
19857566,198575662,2,F,,20220314,20210921,20220323,EXP,,CA-AstraZeneca-2021A724592,ASTRAZENECA,,54,YR,,M,Y,,,20220323,,MD,CA,,EFAVIRENZ,Depression;Drug interaction;Loss of personal independence in daily activities,198575662,OT,,,,,,,,,198575662,1,Bipolar disorder
19864842,198648423,3,F,20080101,20220222,20210922,20220225,EXP,,US-GILEAD-2021-0548532,GILEAD,,49,YR,A,M,Y,63.5,KG,20220225,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood cholesterol increased;Blood creatinine increased;Chronic kidney disease;Depression;Emotional distress;Hypertension;Pain;Pollakiuria;Renal failure,198648423,OT,,,198648423,1,200708,200802,,,198648423,1,HIV infection
19903750,199037502,2,F,,20220311,20211001,20220325,EXP,,CA-APOTEX-2021AP043245,APOTEX,,54,YR,,M,Y,,,20220325,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,199037502,OT,,,,,,,,,199037502,1,HIV infection
19909900,199099002,2,F,,20220118,20211003,20220128,EXP,,CA-APOTEX-2021AP043243,APOTEX,,54,YR,,M,Y,,,20220128,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,199099002,DE,,,,,,,,,199099002,1,HIV infection
19926375,199263752,2,F,,20210927,20211007,20220302,EXP,,CA-JNJFOC-20210959707,JOHNSON AND JOHNSON,,10,YR,C,F,Y,,,20220302,,HP,CA,CA,EFAVIRENZ,Chills;Disease recurrence;Nephropathy toxic,199263752,OT,,,199263752,4,,,12,WK,199263752,1,Histoplasmosis disseminated
19934696,199346962,2,F,,20220308,20211008,20220310,EXP,,CA-ABBVIE-21K-028-4108072-00,ABBVIE,,54,YR,,M,Y,,,20220310,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Loss of personal independence in daily activities,199346962,OT,,,,,,,,,199346962,1,HIV infection
19935668,199356682,2,F,,20220212,20211009,20220216,EXP,,CA-ABBVIE-21K-028-4109826-00,ABBVIE,,54,YR,,M,Y,,,20220216,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,199356682,OT,,,,,,,,,199356682,1,HIV infection
19939207,199392072,2,F,,20211224,20211011,20220106,EXP,,CA-MYLANLABS-2021M1071036,MYLAN,,54,YR,,M,Y,,,20220106,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,199392072,DE,,,,,,,,,199392072,1,Bipolar disorder
19939208,199392082,2,F,,20220207,20211011,20220217,EXP,,CA-MYLANLABS-2021M1071030,MYLAN,,54,YR,,M,Y,,,20220217,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,199392082,OT,,,,,,,,,199392082,1,Bipolar disorder
19974419,199744192,2,F,20210101,20211119,20211020,20220221,EXP,GB-MHRA-EYC 00263325,GB-MYLANLABS-2021M1073649,MYLAN,,71,YR,,M,Y,,,20220221,,MD,GB,GB,EFAVIRENZ,Drug ineffective;Pathogen resistance;Product administration error;Treatment noncompliance;Viral mutation identified;Virologic failure,199744192,OT,,,199744192,1,20191114,,,,199744192,1,HIV infection
20105742,201057423,3,F,20090410,20220215,20211124,20220301,EXP,,US-VIIV HEALTHCARE LIMITED-US2020080421,VIIV,,33,YR,,M,Y,,,20220301,,LW,US,US,SUSTIVA,Chronic kidney disease;Dental caries;Renal failure;Renal impairment;Renal injury;Skeletal injury;Tooth loss,201057423,OT,,,201057423,1,20090121,20160101,2536,DAY,201057423,1,HIV infection
20106011,201060113,3,F,20090410,20220215,20211124,20220301,EXP,,US-GLAXOSMITHKLINE-US2020080421,GLAXOSMITHKLINE,,33,YR,,M,Y,,,20220301,,LW,US,US,SUSTIVA,Chronic kidney disease;Dental caries;Renal failure;Renal impairment;Renal injury;Skeletal injury;Tooth loss,201060113,OT,,,201060113,1,20090121,20160101,2536,DAY,201060113,1,HIV infection
20113711,201137112,2,F,,20220126,20211125,20220204,EXP,,RO-MYLANLABS-2021M1038036,MYLAN,,31,YR,,M,Y,,,20220204,,MD,RO,RO,EFAVIRENZ,Drug ineffective;Virologic failure,201137112,OT,,,,,,,,,201137112,1,HIV infection
20123926,201239262,2,F,20210101,20220322,20211129,20220325,EXP,,GB-GILEAD-2021-0557694,GILEAD,,71,YR,E,M,Y,,,20220325,,MD,GB,GB,EFAVIRENZ,Drug ineffective;Pathogen resistance;Product administration error;Treatment noncompliance;Viral mutation identified;Virologic failure,201239262,OT,,,201239262,1,20191114,201911,,,201239262,1,HIV infection
20125879,201258793,3,F,,20220118,20211129,20220125,EXP,,UG-MYLANLABS-2021M1086327,MYLAN,,,,,F,Y,,,20220125,,HP,UG,UG,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Congenital umbilical hernia;Foetal exposure during pregnancy,201258793,OT,,,201258793,1,20210204,20210203,1032,DAY,201258793,1,HIV infection
20128073,201280732,2,F,20090101,20220317,20211129,20220323,EXP,,US-GILEAD-2021-0557457,GILEAD,,,,A,F,Y,68.027,KG,20220323,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Back pain;Bone demineralisation;Depression;Emotional distress;Fall;Gait disturbance;Hip fracture;Lower limb fracture;Mobility decreased;Osteoporosis;Pain;Renal impairment,201280732,OT,,,201280732,1,2004,200906,,,201280732,1,HIV infection
20144797,201447975,5,F,,20220118,20211203,20220201,EXP,,UG-AUROBINDO-AUR-APL-2021-050077,AUROBINDO,,,,I,F,Y,3.4,KG,20220201,,HP,UG,UG,"EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE",Foetal exposure during pregnancy;Umbilical hernia,201447975,CA,,,201447975,1,20180409,20210203,1032,DAY,201447975,1,HIV infection
20154641,201546412,2,F,20211029,20220104,20211207,20220107,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-126972,BRISTOL MYERS SQUIBB,,51,YR,,M,Y,57,KG,20220107,,MD,DE,DE,EFAVIRENZ,Coronary artery disease,201546412,OT,,,201546412,2,20150422,20150812,113,DAY,201546412,1,Hepatitis C
20214238,202142383,3,F,,20220315,20211221,20220324,EXP,,US-GILEAD-2021-0560646,GILEAD,,,,A,M,Y,,,20220324,,LW,US,US,SUSTIVA,Chronic kidney disease;Renal failure,202142383,OT,,,202142383,1,2014,2018,,,202142383,1,HIV infection
20217592,202175925,5,F,20211120,20220318,20211222,20220324,EXP,,DE-TAKEDA-2021TUS079245,TAKEDA,,,,E,M,Y,,,20220324,,HP,DE,DE,EFAVIRENZ,C-reactive protein increased;Femur fracture,202175925,DS,,,202175925,1,20060214,20190106,4710,DAY,202175925,1,Factor VIII deficiency
20222129,202221292,2,F,,20220225,20211223,20220303,EXP,,CA-ROCHE-2984070,ROCHE,,,,,M,Y,,,20220303,,HP,CA,,SUSTIVA,Depression;Drug interaction,202221292,DE,,,,,,,,,202221292,1,Product used for unknown indication
20279046,202790461,1,I,,20211224,20220103,20220103,EXP,,FR-AUROBINDO-AUR-APL-2021-054104,AUROBINDO,"Kherabi Y, De Castro N, Sellier P-O, Hamet G, Brun A, Digumber M, et al.. Efficacy and safety of efavirenz, raltegravir and dolutegravir in HIV/TB co-infection.. A retrospective cohort study. 2021;22 (Suppl. 3):176 (plus poster)",,,,,Y,,,20220103,,HP,FR,FR,EFAVIRENZ,Pathogen resistance;Virologic failure,202790461,OT,,,,,,,,,202790461,1,Antiretroviral therapy
20280183,202801831,1,I,,20211222,20220103,20220103,EXP,,PT-MYLANLABS-2021M1096034,MYLAN,"Mouro M, Martins A, Soeiro C, Coutinho D, Velez J, Freitas F. et al. Mono and dual therapies in human immunodeficiency virus infection. Data from a district hospital. 2021;16 (2):56-57",,,A,,Y,,,20220103,,MD,PT,PT,EFAVIRENZ,Treatment failure,202801831,OT,,,,,,,,,202801831,1,HIV infection
20289588,202895881,1,I,20211224,20211230,20220104,20220104,EXP,,CA-ABBVIE-21K-028-4217419-00,ABBVIE,,,,,M,Y,,,20220104,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction,202895881,HO,,,,,,,,,202895881,1,Product used for unknown indication
20302097,203020971,1,I,,20211229,20220105,20220105,EXP,,CA-ALVOGEN-2022-ALVOGEN-118067,ALVOGEN,,54,YR,,M,Y,,,20220106,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,203020971,OT,,,,,,,,,203020971,1,Bipolar disorder
20302242,203022421,1,I,,20220103,20220106,20220106,EXP,,CA-ABBVIE-22K-028-4222593-00,ABBVIE,,54,YR,,M,Y,,,20220105,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,203022421,OT,,,,,,,,,203022421,1,Product used for unknown indication
20302661,203026611,1,I,,20211224,20220106,20220106,EXP,,CA-ABBVIE-22K-028-4222525-00,ABBVIE,,54,YR,,M,Y,,,20220106,,CN,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,203026611,DS,,,,,,,,,203026611,1,Bipolar disorder
20303944,203039441,1,I,,20220103,20220106,20220106,EXP,,CA-ABBVIE-22K-028-4222490-00,ABBVIE,,54,YR,,M,Y,,,20220106,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,203039441,OT,,,,,,,,,203039441,1,Bipolar disorder
20304149,203041492,2,F,20120120,20220131,20220106,20220209,EXP,,US-VIIV HEALTHCARE LIMITED-US2020262122,VIIV,,38,YR,,M,Y,77.098,KG,20220209,,LW,US,US,SUSTIVA,Blood creatinine increased;Nephropathy;Renal cyst;Renal failure,203041492,OT,,,203041492,1,20130129,20130314,44,DAY,203041492,1,HIV infection
20306819,203068191,1,I,,20211229,20220106,20220106,EXP,,CA-ALVOGEN-2022-ALVOGEN-118079,ALVOGEN,,54,YR,,M,Y,,,20220107,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,203068191,OT,,,,,,,,,203068191,1,Bipolar disorder
20310617,203106171,1,I,,20220103,20220107,20220107,EXP,,CA-ABBVIE-22K-028-4223963-00,ABBVIE,,54,YR,,M,Y,,,20220107,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,203106171,DE,,,,,,,,,203106171,1,Bipolar disorder
20310738,203107381,1,I,,20211224,20220107,20220107,EXP,,CA-ABBVIE-22K-028-4224361-00,ABBVIE,,54,YR,,M,Y,,,20220107,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction,203107381,DE,,,,,,,,,203107381,1,HIV infection
20311333,203113331,1,I,,20211231,20220107,20220107,EXP,,CA-TEVA-2021-CA-1996519,TEVA,,,,,M,Y,,,20220108,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,203113331,HO,,,,,,,,,203113331,1,Product used for unknown indication
20311334,203113341,1,I,,20211231,20220107,20220107,EXP,,CA-TEVA-2021-CA-1996525,TEVA,,54,YR,A,M,Y,,,20220108,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,203113341,OT,,,,,,,,,203113341,1,HIV infection
20311361,203113611,1,I,,20211231,20220107,20220107,EXP,,CA-TEVA-2021-CA-1996533,TEVA,,54,YR,A,M,Y,,,20220108,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,203113611,OT,,,,,,,,,203113611,1,HIV infection
20311366,203113661,1,I,,20211231,20220107,20220107,EXP,,CA-TEVA-2021-CA-1996528,TEVA,,,,,M,Y,,,20220108,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,203113661,HO,,,,,,,,,203113661,1,Product used for unknown indication
20311370,203113701,1,I,,20211231,20220107,20220107,EXP,,CA-TEVA-2021-CA-1996518,TEVA,,54,YR,A,M,Y,,,20220108,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,203113701,DE,,,,,,,,,203113701,1,HIV infection
20317458,203174581,1,I,,20211228,20220110,20220110,EXP,,CN-GLAXOSMITHKLINE-CN2021APC264803,GLAXOSMITHKLINE,,,,,F,Y,,,20220110,,HP,CN,CN,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,203174581,OT,,,203174581,1,20180907,,,,203174581,1,Acquired immunodeficiency syndrome
20317460,203174601,1,I,,20211228,20220110,20220110,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2021APC264803,VIIV,,,,,F,Y,,,20220110,,HP,CN,CN,EFAVIRENZ,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,203174601,OT,,,203174601,1,20180907,,,,203174601,1,Acquired immunodeficiency syndrome
20324129,203241291,1,I,20080101,20220105,20220111,20220111,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-144769,BRISTOL MYERS SQUIBB,"Patel N, Childs K. The legacy of older ART agents: multiple consequences of decades of NRTI therapy. HIV Medicine. 2021;22(SUPPL 3):308",52,YR,,F,Y,,,20220111,,MD,GB,GB,EFAVIRENZ,Neurotoxicity,203241291,OT,,,203241291,1,2008,,,,203241291,1,HIV infection
20324157,203241571,1,I,20070101,20220105,20220111,20220111,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-144768,BRISTOL MYERS SQUIBB,"Patel N, Childs K. The legacy of older ART agents: multiple consequences of decades of NRTI therapy. HIV Medicine. 2021;22(SUPPL 3):308",52,YR,,F,Y,,,20220111,,MD,GB,GB,EFAVIRENZ,Hypophosphataemia,203241571,OT,,,203241571,1,2007,,,,203241571,1,HIV infection
20329120,203291201,1,I,20201106,20220107,20220112,20220112,EXP,,ZA-MYLANLABS-2022M1002330,MYLAN,,,,,F,Y,,,20220112,,HP,ZA,ZA,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,203291201,OT,,,203291201,1,20200910,20200909,1281,DAY,203291201,1,Product used for unknown indication
20332604,203326041,1,I,,20220110,20220113,20220113,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-004967,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20220113,,HP,CA,CA,SUSTIVA,Death,203326041,OT,,,,,,,,,203326041,1,HIV infection
20332734,203327341,1,I,,20220110,20220113,20220113,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-003921,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20220113,,HP,CA,CA,SUSTIVA,Death,203327341,OT,,,,,,,,,203327341,1,Bipolar disorder
20333355,203333551,1,I,,20220107,20220113,20220113,EXP,,US-MYLANLABS-2022M1002777,MYLAN,"Brasher WP, Bvumbwe M, Kazembe PN. Infection or drug toxicity? Acute ataxia and encephalopathy after uncomplicated falciparum malaria and efavirenz dose adjustment. Malawi-Med-J 2020;32(4):229-231.",16,YR,,M,Y,,,20220113,,HP,US,US,EFAVIRENZ,Ataxia;Encephalopathy;Hypersensitivity;Toxicity to various agents,203333551,HO,,,203333551,1,2012,,,,203333551,1,HIV infection WHO clinical stage I
20336620,203366201,1,I,20210820,20220112,20220114,20220114,EXP,,ZA-GILEAD-2022-0565310,GILEAD,,27,YR,A,F,Y,,,20220114,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,203366201,OT,,,203366201,1,20161116,20211020,1799,DAY,203366201,1,HIV infection
20338234,203382341,1,I,,20220104,20220115,20220115,EXP,,GB-MACLEODS PHARMA UK LTD-MAC2022034048,MACLEODS,"Patel N, Childs K.. The legacy of older ART agents: Multiple consequences of decades of NRTI therapy. HIV Medicine. 2021;22(3)",,,,,Y,,,20220115,,MD,GB,GB,EFAVIRENZ,Hepatic encephalopathy;Hypophosphataemia;Lactic acidosis;Neuropathy peripheral;Neurotoxicity;Portal hypertension;Portal vein thrombosis;Toxicity to various agents,203382341,HO,,,,,,,,,203382341,1,HIV infection
20340755,203407552,2,F,20210615,20220202,20220117,20220204,EXP,,ZA-GILEAD-2022-0565607,GILEAD,,23,YR,A,F,Y,,,20220204,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL MALEATE,Maternal exposure during pregnancy;Stillbirth,203407552,OT,,,203407552,1,20180118,20210301,1138,DAY,203407552,1,HIV infection
20342745,203427451,1,I,,20220113,20220117,20220117,PER,,US-ELI_LILLY_AND_COMPANY-US202201005712,ELI LILLY AND CO,,,,,F,Y,,,20220117,,CN,US,US,EFAVIRENZ,Visual impairment,,,,,203427451,1,2009,,,,203427451,1,Product used for unknown indication
20346383,203463831,1,I,20211121,20220112,20220118,20220118,EXP,,ZA-MYLANLABS-2022M1003728,MYLAN,,27,YR,,F,Y,,,20220118,,CN,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,203463831,OT,,,203463831,1,20161116,20211020,1800,DAY,203463831,1,HIV infection
20349773,203497731,1,I,,20220108,20220119,20220119,EXP,CA-MHPD-E2B_03530662,CA-Accord-250153,ACCORD,,54,YR,,M,Y,,,20220119,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,203497731,OT,,,,,,,,,203497731,1,Product used for unknown indication
20356008,203560081,1,I,,20220107,20220120,20220120,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-00480,LUPIN,"Brasher WP, Bvumbwe M, Kazembe PN. Infection or drug toxicity. Acute ataxia and encephalopathy after uncomplicated falciparum malaria and efavirenz dose adjustment. Malawi Medical Journal. 2020;32(4):229-231",16,YR,,M,Y,,,20220120,,HP,US,US,EFAVIRENZ,Hypersensitivity,,,,,203560081,2,2012,,,,203560081,1,Antibiotic prophylaxis
20359299,203592991,1,I,20210615,20220114,20220121,20220121,EXP,,ZA-STRIDES ARCOLAB LIMITED-2022SP000446,STRIDES,,23,YR,,F,Y,,,20220121,,HP,ZA,ZA,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,203592991,OT,,,203592991,1,20210118,,,,203592991,1,HIV infection
20368241,203682411,1,I,,20220110,20220124,20220124,PER,,ZA-LUPIN PHARMACEUTICALS INC.-2022-00645,LUPIN,"Acquah R, Mohr-Holland E, Daniels J, Furin J, Loveday M, Mudaly V, et al. Outcomes of Children Born to Pregnant Women With Drug-resistant Tuberculosis Treated With Novel Drugs in Khayelitsha, South Africa: A Report of Five Patients. Pediatric Infectious Disease Journal. 2021;40(5):e191-e192",,,A,F,Y,,,20220124,,MD,ZA,ZA,"EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE",Exposure during pregnancy;Normal newborn,,,,,,,,,,,203682411,1,Tuberculosis
20369608,203696081,1,I,,20220117,20220124,20220124,EXP,,US-MYLANLABS-2022M1005842,MYLAN,"Nusbaum KB, Kaffenberger BH, Paradiso BS MM, Sopkovich JA, Daou H, Seminario-Vidal L, et al. Dupilumab for treatment of atopic dermatitis in patients living with HIV: a case series. Int-J-Dermatol 2021;60(9):e344-e346.",68,YR,,,Y,,,20220124,,MD,US,US,EFAVIRENZ,Drug ineffective for unapproved indication;Off label use,203696081,OT,,,,,,,,,203696081,1,Dermatitis atopic
20369610,203696101,1,I,,20220117,20220124,20220124,EXP,,US-MYLANLABS-2022M1005868,MYLAN,"Nusbaum KB, Kaffenberger BH, Paradiso BS MM, Sopkovich JA, Daou H, Seminario-Vidal L, et al. Dupilumab for treatment of atopic dermatitis in patients living with HIV: a case series. Int-J-Dermatol 2021;60(9):e344-e346.",37,YR,,,Y,,,20220124,,MD,US,US,EFAVIRENZ,Off label use;Treatment failure,203696101,OT,,,,,,,,,203696101,1,Dermatitis atopic
20371509,203715091,1,I,,20220116,20220124,20220124,EXP,,CA-TEVA-2022-CA-2001581,TEVA,,54,YR,A,M,Y,,,20220124,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Loss of personal independence in daily activities,203715091,OT,,,,,,,,,203715091,1,HIV infection
20371511,203715111,1,I,,20220116,20220124,20220124,EXP,,CA-TEVA-2022-CA-2001355,TEVA,,54,YR,A,M,Y,,,20220124,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,203715111,DE,,,,,,,,,203715111,1,Product used for unknown indication
20371513,203715131,1,I,,20220116,20220124,20220124,EXP,,CA-TEVA-2022-CA-2001358,TEVA,,54,YR,A,M,Y,,,20220124,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,203715131,DE,,,,,,,,,203715131,1,HIV infection
20372906,203729061,1,I,20210615,20220113,20220125,20220125,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-007273,BRISTOL MYERS SQUIBB,,23,YR,,F,Y,,,20220125,,HP,ZA,ZA,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,203729061,OT,,,203729061,1,20210301,,,,203729061,1,HIV infection
20372999,203729992,2,F,20210615,20220114,20220125,20220125,EXP,,ZA-CIPLA LTD.-2022ZA00255,CIPLA,,,,,,Y,,,20220125,,HP,ZA,ZA,EFAVIRENZ,Exposure during pregnancy;Stillbirth,203729992,OT,,,203729992,1,20210118,,,,203729992,1,HIV infection
20373955,203739551,1,I,20211121,20220113,20220125,20220125,EXP,,ZA-MACLEODS PHARMA UK LTD-MAC2022034125,MACLEODS,,,,,,Y,,,20220125,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,203739551,OT,,,203739551,1,20161116,20211020,1799,DAY,203739551,1,HIV infection
20379777,203797772,2,F,20210615,20220201,20220126,20220215,EXP,,ZA-MYLANLABS-2022M1003734,MYLAN,,23,YR,,F,Y,,,20220215,,CN,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL MALEATE,Maternal exposure during pregnancy;Stillbirth,203797772,OT,,,203797772,1,20210301,20210301,1139,DAY,203797772,1,HIV infection
20381106,203811062,2,F,,20220201,20220127,20220214,EXP,,ZA-AUROBINDO-AUR-APL-2022-001596,AUROBINDO,,23,YR,,F,Y,,,20220214,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL MALEATE,Maternal exposure during pregnancy;Stillbirth,203811062,OT,,,203811062,1,20210118,20210301,43,DAY,203811062,1,HIV infection
20381382,203813822,2,F,,20220201,20220127,20220202,EXP,,CA-ABBVIE-22K-028-4247868-00,ABBVIE,,52,YR,,M,Y,,,20220202,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,203813822,OT,,,,,,,,,203813822,1,HIV infection
20381882,203818823,3,F,20210615,20220202,20220127,20220216,EXP,,ZA-MACLEODS PHARMA UK LTD-MAC2022034157,MACLEODS,,,,,,Y,,,20220216,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL MALEATE,Maternal exposure during pregnancy;Stillbirth,203818823,OT,,,203818823,1,20180118,20210301,1138,DAY,203818823,1,HIV infection
20385983,203859832,2,F,,20220201,20220127,20220210,EXP,,US-TEVA-2022-US-2001129,TEVA,"Brasher WP, Bvumbwe M, Kazembe PN. Infection or drug toxicity? Acute ataxia and encephalopathy after uncomplicated falciparum malaria and efavirenz dose adjustment. Malawi-Med-J 2020;32(4):229-231.",16,YR,T,M,Y,,,20220210,,HP,US,US,EFAVIRENZ,Ataxia;Encephalopathy;Hypersensitivity;Toxicity to various agents,203859832,HO,,,203859832,2,2012,,,,203859832,1,Antibiotic prophylaxis
20393638,203936381,1,I,,20220126,20220128,20220128,EXP,,CA-BAUSCH-BL-2022-002759,BAUSCH AND LOMB,,54,YR,,M,Y,,,20220128,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Loss of personal independence in daily activities,203936381,OT,,,,,,,,,203936381,1,Bipolar disorder
20393642,203936421,1,I,,20220126,20220128,20220128,EXP,,CA-BAUSCH-BL-2022-002767,BAUSCH AND LOMB,,54,YR,,M,Y,,,20220128,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,203936421,DE,,,,,,,,,203936421,1,Bipolar disorder
20394039,203940391,1,I,,20220117,20220129,20220129,EXP,,US-AUROBINDO-AUR-APL-2022-001768,AUROBINDO,"Brasher WP, Bvumbwe M, Kazembe PN.. Infection or drug toxicity? Acute ataxia and encephalopathy after uncomplicated falciparum malaria and efavirenz dose adjustment. Malawi Medical Journal. 2020;32 (4):229-231",16,YR,,M,Y,,,20220129,,HP,US,US,EFAVIRENZ,Ataxia;Encephalopathy;Toxicity to various agents,203940391,OT,,,,,,,,,203940391,1,HIV infection
20404416,204044161,1,I,,20220126,20220131,20220131,EXP,,CA-BAUSCH-BL-2022-002770,BAUSCH AND LOMB,,54,YR,,M,Y,,,20220131,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,204044161,DE,,,,,,,,,204044161,1,Product used for unknown indication
20411280,204112801,1,I,,20220126,20220201,20220201,EXP,,CA-BAUSCH-BL-2021-006063,BAUSCH AND LOMB,,44,YR,,M,Y,,,20220201,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,204112801,HO,,,204112801,14,,,365,DAY,204112801,1,Depression
20411454,204114542,2,F,,20220210,20220201,20220223,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-010603,BRISTOL MYERS SQUIBB,How SARS-CoV-2 can evolve into a variant of concern in an immunocompromised individual. Le Monde.fr. 2022,4,DEC,,F,Y,,,20220223,,HP,ZA,ZA,EFAVIRENZ,COVID-19,204114542,HO,,,,,,,,,204114542,1,HIV infection
20414162,204141623,3,F,,20220317,20220201,20220330,EXP,,RO-AUROBINDO-AUR-APL-2018-040860,AUROBINDO,,26,YR,,M,Y,,,20220330,,MD,RO,RO,EFAVIRENZ,Lipodystrophy acquired;Virologic failure,204141623,OT,,,,,,,,,204141623,1,HIV infection
20414987,204149872,2,F,,20220201,20220202,20220211,EXP,,US-JNJFOC-20220149634,JOHNSON AND JOHNSON,,52,YR,A,M,Y,,,20220211,,HP,US,US,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,204149872,OT,,,,,,,,,204149872,1,HIV infection
20415000,204150001,1,I,,20220126,20220202,20220202,EXP,,TR-GILEAD-2022-0567170,GILEAD,,,,A,F,Y,,,20220202,,MD,TR,TR,EFAVIRENZ,Abortion spontaneous;Drug ineffective;Hepatitis B DNA increased;Maternal exposure during pregnancy,204150001,OT,,,,,,,,,204150001,1,Hepatitis B
20417236,204172361,1,I,,20220126,20220202,20220202,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK054554,VIIV,,44,YR,,M,Y,,,20220202,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,204172361,HO,,,,,,,,,204172361,1,Depression
20417297,204172971,1,I,,20220126,20220202,20220202,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK054554,GLAXOSMITHKLINE,,44,YR,,M,Y,,,20220202,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,204172971,OT,,,,,,,,,204172971,1,Depression
20419904,204199041,1,I,20160101,20220121,20220203,20220203,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-010896,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20220203,,LW,US,US,SUSTIVA,Chronic kidney disease;Gastrointestinal disorder;Pain;Renal failure;Renal injury;Skeletal injury,204199041,OT,,,204199041,2,201410,,,,204199041,1,Product used for unknown indication
20427863,204278631,1,I,,20220124,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00525,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12): e026136:1 to 15",,,,,Y,,,20220204,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204278631,OT,,,,,,,,,204278631,1,HIV infection
20427910,204279101,1,I,,20220124,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00527,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLOS ONE. 2021;16(12):1 to 15",,,,,Y,,,20220204,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204279101,OT,,,,,,,,,204279101,1,HIV infection
20427978,204279781,1,I,,20220124,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00529,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12): e026136:1 to 15",,,,,Y,,,20220204,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204279781,OT,,,,,,,,,204279781,1,HIV infection
20428088,204280881,1,I,,20220124,20220204,20220204,EXP,,TZ-CIPLA LTD.-2022TZ00531,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16 (12):e026136:1 to 15",,,,,Y,,,20220204,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204280881,OT,,,,,,,,,204280881,1,HIV infection
20428128,204281281,1,I,,20220124,20220204,20220204,EXP,,TZ-CIPLA LTD.-2022TZ00535,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T, et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLOS ONE. 2021;16(12):e0261367:1 to 15",,,,,Y,,,20220204,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204281281,OT,,,,,,,,,204281281,1,HIV infection
20428194,204281941,1,I,,20220124,20220204,20220204,EXP,,TZ-CIPLA LTD.-2022TZ00536,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLOS ONE. 2021;16(12):e0261367:1 to 15",,,,,Y,,,20220204,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204281941,OT,,,,,,,,,204281941,1,HIV infection
20428221,204282211,1,I,,20220124,20220204,20220204,EXP,,TZ-CIPLA LTD.-2022TZ00537,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12): e026136:1 to 15",,,,,Y,,,20220204,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204282211,OT,,,,,,,,,204282211,1,HIV infection
20428280,204282801,1,I,,20220124,20220204,20220204,EXP,,TZ-CIPLA LTD.-2022TZ00538,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16 (12):1 to 15",,,,,Y,,,20220204,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204282801,OT,,,,,,,,,204282801,1,HIV infection
20428338,204283381,1,I,,20220124,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00539,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12):e0261367:1 to 15",,,,,Y,,,20220204,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204283381,OT,,,,,,,,,204283381,1,HIV infection
20428395,204283951,1,I,,20220124,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00540,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T, et al. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLOS ONE. 2021;16(12):1 to 15",,,,,Y,,,20220204,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204283951,OT,,,,,,,,,204283951,1,HIV infection
20428492,204284921,1,I,,20220124,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00541,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12):1 to 15",,,,,Y,,,20220204,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204284921,OT,,,,,,,,,204284921,1,HIV infection
20428538,204285381,1,I,,20220124,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00542,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12):e0261367:1 to 15",,,,,Y,,,20220204,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204285381,OT,,,,,,,,,204285381,1,HIV infection
20428561,204285611,1,I,,20220124,20220204,20220204,EXP,,TZ-CIPLA LTD.-2022TZ00543,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12):1 to 15",,,,,Y,,,20220204,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204285611,OT,,,,,,,,,204285611,1,HIV infection
20428608,204286081,1,I,,20220124,20220204,20220204,EXP,,TZ-CIPLA LTD.-2022TZ00544,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLOS ONE. 2021;16 (12):1 to 15",,,,,Y,,,20220204,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204286081,OT,,,,,,,,,204286081,1,HIV infection
20428667,204286671,1,I,,20220124,20220204,20220204,EXP,,TZ-CIPLA LTD.-2022TZ00546,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12):e0261367:1 to 15",,,,,Y,,,20220204,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204286671,OT,,,,,,,,,204286671,1,HIV infection
20429133,204291331,1,I,,20220124,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00526,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12):1 to 15",,,,,Y,,,20220204,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204291331,OT,,,,,,,,,204291331,1,HIV infection
20429247,204292471,1,I,,20220125,20220204,20220204,EXP,,US-VIIV HEALTHCARE LIMITED-US2010000382,VIIV,,52,YR,,M,Y,,,20220204,,HP,CA,US,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,204292471,OT,,,204292471,3,,,9668,DAY,204292471,1,HIV infection
20429361,204293611,1,I,,20220125,20220204,20220204,EXP,,US-GLAXOSMITHKLINE-US2010000382,GLAXOSMITHKLINE,,52,YR,,M,Y,,,20220204,,HP,CA,US,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,204293611,OT,,,204293611,3,,,9668,DAY,204293611,1,HIV infection
20429398,204293981,1,I,,20220124,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00532,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12): e026136:1 to 15",,,,,Y,,,20220204,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204293981,OT,,,,,,,,,204293981,1,HIV infection
20429400,204294001,1,I,,20220124,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00533,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12):e0261367:1 to 15",,,,,Y,,,20220204,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204294001,OT,,,,,,,,,204294001,1,HIV infection
20429401,204294011,1,I,,20220124,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00548,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLOS ONE. 2021;16 (12):1 to 15",,,,,Y,,,20220204,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204294011,OT,,,,,,,,,204294011,1,HIV infection
20429402,204294021,1,I,,20220124,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00528,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLOS ONE. 2021;16 (12):e026136:1 to 15",,,,,Y,,,20220204,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204294021,OT,,,,,,,,,204294021,1,HIV infection
20429403,204294031,1,I,,20220124,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00530,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;6 (12):1 to15",,,,,Y,,,20220204,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204294031,OT,,,,,,,,,204294031,1,HIV infection
20429405,204294051,1,I,,20220124,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00547,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12):1 to 15",,,,,Y,,,20220204,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204294051,OT,,,,,,,,,204294051,1,HIV infection
20429406,204294061,1,I,,20220124,20220204,20220204,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00549,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16 (12):1 to 15",,,,,Y,,,20220204,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204294061,OT,,,,,,,,,204294061,1,HIV infection
20431576,204315762,2,F,,20220207,20220204,20220214,EXP,,IN-TAKEDA-2022TUS007346,TAKEDA,"Kachhwaha A, Rohila AK, Tripathi S, Meena DS, Khichar, MS Kumar D, et al. Acute myocardial infarction in hemophilia A with HIV and hyperhomocysteinemia- a rare case report. CARDIOVASCULAR AND HEMATOLOGICAL DISORDERS DRUG TARGETS. 2021;xx:1-3",42,YR,,M,Y,,,20220214,,HP,IN,IN,EFAVIRENZ,Acute myocardial infarction,204315762,HO,,,,,,,,,204315762,1,Factor VIII deficiency
20432545,204325452,2,F,20180508,20220207,20220204,20220215,EXP,,TR-GILEAD-2022-0568528,GILEAD,,56,YR,A,M,Y,70,KG,20220215,,MD,TR,TR,EFAVIRENZ,Genotype drug resistance test positive;Osteonecrosis;Osteopenia;Osteoporosis,204325452,OT,,,204325452,1,2012,,,,204325452,1,HIV infection
20435782,204357821,1,I,,20220124,20220207,20220207,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00551,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12): e026136:1 to 15",,,,,Y,,,20220207,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204357821,OT,,,,,,,,,204357821,1,HIV infection
20435860,204358601,1,I,,20220124,20220207,20220207,EXP,,TZ-CIPLA LTD.-2022TZ00552,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12): e026136:1 to 15",,,,,Y,,,20220207,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204358601,OT,,,,,,,,,204358601,1,HIV infection
20435886,204358861,1,I,,20220124,20220207,20220207,EXP,,TZ-CIPLA LTD.-2022TZ00553,CIPLA,"Mapesi H, Paris DH, Okuma J, Franzeck F, Wilson HI, Senkoro E et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLOS ONE. 2021;16(12):e0261367:1 to 15",,,,,Y,,,20220207,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204358861,OT,,,,,,,,,204358861,1,HIV infection
20435983,204359831,1,I,,20220124,20220207,20220207,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00555,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12): e026136:1 to 15",,,,,Y,,,20220207,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204359831,OT,,,,,,,,,204359831,1,HIV infection
20436459,204364593,3,F,20180101,20220311,20220207,20220322,EXP,,MY-CIPLA (EU) LIMITED-2022MY00598,CIPLA,"Pazil SN, Zulkifli MM, Muhamad R, Chen LK. A man with hypoesthetic skin lesions: a case report of immune reconstitution inflammatory syndrome. Iran J Dermatol. 2021;24:234 to 237",,,,,Y,,,20220322,,MD,MY,MY,EFAVIRENZ,Disorientation;Immune reconstitution inflammatory syndrome;Nausea;Tuberculoid leprosy;Type 1 lepra reaction;Vomiting,204364593,OT,,,204364593,1,20181101,2018,,,204364593,1,HIV infection
20436791,204367911,1,I,,20220131,20220207,20220207,EXP,,MY-GILEAD-2022-0568147,GILEAD,"Pazil S, Zulkifli M, Muhamad R., Chen L.. A man with hypoesthetic skin lesions: a case report of immune reconstitution inflammatory syndrome. Iranian Journal of Dermatology. 2021;24(3):234-237. doi:10.22034/ijd.2021.136582",39,YR,A,M,Y,,,20220207,,MD,MY,MY,EFAVIRENZ,Disorientation;Nausea;Vomiting,204367911,OT,,,204367911,1,201811,,,,204367911,1,HIV infection
20438722,204387221,1,I,,20220202,20220207,20220207,EXP,,ZA-MYLANLABS-2022M1010506,MYLAN,"Manickchund N, Du Plessis C, John MA-A, Manzini TC, Gosnell BI, Moosa M-YS. A case series of emtricitabine-induced pure red cell aplasia. South-Afr-J-HIV-Med 2021;22:No. 1.",23,YR,,F,Y,,,20220207,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell;Cross sensitivity reaction,204387221,HO,,,,,,,,,204387221,1,HIV infection
20438723,204387231,1,I,,20220202,20220207,20220207,EXP,,ZA-MYLANLABS-2022M1010486,MYLAN,"Manickchund N, Du Plessis C, John MA-A, Manzini TC, Gosnell BI, Moosa M-YS. A case series of emtricitabine-induced pure red cell aplasia. South-Afr-J-HIV-Med 2021;22:No. 1.",61,YR,,F,Y,,,20220207,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,204387231,HO,,,,,,,,,204387231,1,HIV infection
20438724,204387241,1,I,,20220202,20220207,20220207,EXP,,ZA-MYLANLABS-2022M1010502,MYLAN,"Manickchund N, Du Plessis C, John MA-A, Manzini TC, Gosnell BI, Moosa M-YS. A case series of emtricitabine-induced pure red cell aplasia. South-Afr-J-HIV-Med 2021;22:No. 1.",37,YR,,F,Y,,,20220207,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,204387241,HO,,,,,,,,,204387241,1,HIV infection
20438725,204387251,1,I,,20220202,20220207,20220207,EXP,,ZA-MYLANLABS-2022M1010501,MYLAN,"Manickchund N, Du Plessis C, John MA-A, Manzini TC, Gosnell BI, Moosa M-YS. A case series of emtricitabine-induced pure red cell aplasia. South-Afr-J-HIV-Med 2021;22:No. 1.",35,YR,,F,Y,,,20220207,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,204387251,HO,,,,,,,,,204387251,1,HIV infection
20438726,204387261,1,I,,20220202,20220207,20220207,EXP,,ZA-MYLANLABS-2022M1010487,MYLAN,"Manickchund N, Du Plessis C, John MA-A, Manzini TC, Gosnell BI, Moosa M-YS. A case series of emtricitabine-induced pure red cell aplasia. South-Afr-J-HIV-Med 2021;22:No. 1.",48,YR,,F,Y,,,20220207,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,204387261,HO,,,,,,,,,204387261,1,HIV infection
20438727,204387271,1,I,,20220202,20220207,20220207,EXP,,ZA-MYLANLABS-2022M1010500,MYLAN,"Manickchund N, Du Plessis C, John MA-A, Manzini TC, Gosnell BI, Moosa M-YS. A case series of emtricitabine-induced pure red cell aplasia. South-Afr-J-HIV-Med 2021;22:No. 1.",55,YR,,F,Y,,,20220207,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,204387271,HO,,,,,,,,,204387271,1,HIV infection
20439449,204394491,1,I,,20220202,20220207,20220207,EXP,,ZA-LUPIN PHARMACEUTICALS INC.-2022-01516,LUPIN,"Manickchund N, Du Plessis C, John MA-A, Manzini TC, Gosnell BI, Moosa M-YS. A case series of emtricitabine-induced pure red cell aplasia. Southern African Journal of HIV Medicine. 2021;22(1):1-4",23,YR,,F,Y,,,20220207,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell;Cross sensitivity reaction,204394491,OT,,,,,,,,,204394491,1,HIV infection
20441868,204418681,1,I,,20220124,20220208,20220208,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00561,CIPLA,"Mapesi H, Paris DH, Okuma J, Franzeck F, Wilson HI, Senkoro E et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLOS ONE. 2021;16(12): e026136:1 to 15",,,,,Y,,,20220208,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204418681,OT,,,,,,,,,204418681,1,HIV infection
20441869,204418691,1,I,,20220124,20220208,20220208,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00558,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16 (12):1 to 15",,,,,Y,,,20220208,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204418691,OT,,,,,,,,,204418691,1,HIV infection
20441875,204418751,1,I,,20220124,20220208,20220208,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00562,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLOS ONE. 2021;16 (12):1 to 15",,,,,Y,,,20220208,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204418751,OT,,,,,,,,,204418751,1,HIV infection
20441879,204418791,1,I,,20220124,20220208,20220208,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ00556,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al.. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12):e0261367:1 to 15",,,,,Y,,,20220208,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204418791,OT,,,,,,,,,204418791,1,HIV infection
20441881,204418811,1,I,,20220124,20220208,20220208,EXP,,TZ-CIPLA LTD.-2022TZ00563,CIPLA,"Mapesi H, Okuma J, Franzeck F, Wilson HI, Senkoro E, Byakuzana T et al. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. PLoS ONE. 2021;16(12):e0261367:1 to 15",,,,,Y,,,20220208,,HP,TZ,TZ,EFAVIRENZ,Renal impairment,204418811,OT,,,,,,,,,204418811,1,HIV infection
20445774,204457741,1,I,20220119,20220124,20220208,20220208,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-011151,BRISTOL MYERS SQUIBB,,4,YR,,F,Y,18.6,KG,20220208,,HP,US,US,SUSTIVA,Prescribed underdose;Product availability issue,,,,,204457741,1,20211215,,,,204457741,1,HIV infection
20448184,204481841,1,I,,20220126,20220209,20220209,EXP,,KZ-AUROBINDO-AUR-APL-2022-002874,AUROBINDO,,41,YR,,M,Y,,,20220209,,CN,KZ,KZ,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Connective tissue disorder;Injury;Musculoskeletal disorder;Poisoning;Procedural complication,204481841,OT,,,204481841,1,20210505,20211205,215,DAY,204481841,1,HIV infection
20448824,204488241,1,I,20180101,20220201,20220209,20220209,EXP,,MY-STRIDES ARCOLAB LIMITED-2022SP001108,STRIDES,"Pazil SN, Zulkifli MM, Muhamad R, Chen LK. A man with hypoesthetic skin lesions: a case report of immune reconstitution inflammatory syndrome. Iranian-J-Dermatol. 2021;24(3):234-237",39,YR,,M,Y,,,20220209,,MD,MY,MY,EFAVIRENZ,Disorientation;Immune reconstitution inflammatory syndrome;Nausea;Tuberculoid leprosy;Vomiting,204488241,OT,,,204488241,1,201811,,,,204488241,1,HIV infection
20454920,204549201,1,I,20190101,20220201,20220210,20220210,EXP,,MY-MYLANLABS-2022M1011013,MYLAN,"Pazil SN, Zulkifli MM, Muhamad R, Chen LK. A man with hypoesthetic skin lesions: a case report of immune reconstitution inflammatory syndrome. Iranian-J-Dermatol 2021;24(3):234-237.",39,YR,,M,Y,,,20220210,,MD,MY,MY,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Tuberculoid leprosy,204549201,OT,,,204549201,1,201811,,,,204549201,1,HIV infection
20460733,204607331,1,I,20190101,20220201,20220211,20220211,PER,,MY-LUPIN PHARMACEUTICALS INC.-2022-01590,LUPIN,"Pazil SN, Zulkifli MM, Muhamad R, Chen LK. A man with hypoesthetic skin lesions: a case report of immune reconstitution inflammatory syndrome. Iranian Journal of Dermatology. 2021;24(3):234-237",39,YR,,M,Y,,,20220211,,HP,MY,MY,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Tuberculoid leprosy;Type 1 lepra reaction,204607331,OT,,,204607331,1,201811,,,,204607331,1,HIV infection
20461565,204615651,1,I,,20220208,20220211,20220211,EXP,,CA-AstraZeneca-2022A063503,ASTRAZENECA,,54,YR,,M,Y,,,20220211,,MD,CA,,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities;Product use in unapproved indication,204615651,OT,,,,,,,,,204615651,1,Bipolar disorder
20467373,204673733,3,F,20180101,20220311,20220214,20220324,EXP,,MY-AUROBINDO-AUR-APL-2022-003868,AUROBINDO,"Zulkifli MM,Pazil SN, Muhamad R, Chen LK.. A man with hypoesthetic skin lesions: a case report of immune reconstitution inflammatory syndrome.. Iranian Journal of Dermatology.. 2021;24 (3):234-7",39,YR,,M,Y,66.5,KG,20220324,,MD,MY,MY,EFAVIRENZ,Disorientation;Immune reconstitution inflammatory syndrome;Nausea;Tuberculoid leprosy;Type 1 lepra reaction;Vomiting,204673733,HO,,,204673733,1,20181111,2018,,,204673733,1,HIV infection
20471020,204710202,2,F,20180101,20220314,20220214,20220324,EXP,,MY-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-015910,BRISTOL MYERS SQUIBB,"Pazil SN, Zulkifli MM, Muhamad R, Chen LK. A man with hypoesthetic skin lesions: a case report of immune reconstitution inflammatory syndrome. Iranian Journal of Dermatology 2021;24(3):234-7.",39,YR,A,M,Y,66.5,KG,20220324,,MD,MY,MY,EFAVIRENZ,Disorientation;Immune reconstitution inflammatory syndrome;Nausea;Tuberculoid leprosy;Type 1 lepra reaction;Vomiting,204710202,OT,,,204710202,1,201811,,,,204710202,1,HIV infection
20474775,204747751,1,I,20120120,20220131,20220215,20220215,EXP,,US-VIIV HEALTHCARE LIMITED-US2022AMR024542,VIIV,,38,YR,,M,Y,77.1,KG,20220215,,CN,US,US,SUSTIVA,Blood creatinine increased;Nephropathy;Renal cyst;Renal failure,204747751,OT,,,204747751,1,20130129,20130314,44,DAY,204747751,1,HIV infection
20474789,204747892,2,F,20180101,20220311,20220215,20220324,EXP,,MY-MACLEODS PHARMACEUTICALS US LTD-MAC2022034353,MACLEODS,"Pazil SN, Zulkifli MM, Muhamad R, Chen LK.. A man with hypoesthetic skin lesions: a case report of immune reconstitution inflammatory syndrome. Iranian Journal of Dermatology. 2021;24(3):234-7",,,,,Y,,,20220324,,MD,MY,MY,EFAVIRENZ,Disorientation;Immune reconstitution inflammatory syndrome;Nausea;Tuberculoid leprosy;Type 1 lepra reaction;Vomiting,204747892,HO,,,204747892,1,20181101,2018,,,204747892,1,HIV infection
20477422,204774221,1,I,,20210616,20220215,20220215,PER,,US-CIPLA LTD.-2021US04453,CIPLA,,,,,,Y,,,20220216,,HP,US,US,EFAVIRENZ,Exposure during pregnancy;No adverse event,,,,,,,,,,,204774221,1,Antiretroviral therapy
20478799,204787991,1,I,20130101,20220210,20220216,20220216,EXP,,US-GILEAD-2022-0569621,GILEAD,,62,YR,A,M,Y,,,20220216,,CN,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Bone density decreased;Leg amputation,204787991,DS,,,204787991,1,2013,2015,,,204787991,1,HIV infection
20482301,204823011,1,I,,20220207,20220216,20220216,EXP,,ZA-HETERO-HET2022ZA00342,HETERO,"Manickchund N, Du PC, John MA, Manzini TC, Gosnell BI, Moosa MY. A case series of emtricitabine-induced pure red cell aplasia. Southern African Journal of HIV Medicine. 2021;22(1):1-4",61,YR,,F,Y,,,20220217,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,204823011,OT,,,204823011,1,,,8,MON,204823011,1,HIV infection
20482318,204823181,1,I,,20220207,20220216,20220216,EXP,,ZA-HETERO-HET2022ZA00343,HETERO,"Manickchund N, Du Plessis C, John MA, Manzini TC, Gosnell BI, Moosa M-YS.. A case series of emtricitabine-induced pure red cell aplasia. Southern African Journal of HIV Medicine. 2021;22(1):1-4",48,YR,,F,Y,,,20220217,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,204823181,OT,,,204823181,1,,,5,MON,204823181,1,HIV infection
20482319,204823191,1,I,,20220207,20220216,20220216,EXP,,ZA-HETERO-HET2022ZA00345,HETERO,"Manickchund N, Du PC, John MA, Manzini TC, Gosnell BI, et al.,. A case series of emtricitabine-induced pure red cell aplasia. Southern African Journal of HIV Medicine. 2021;22(1):1-4",35,YR,,F,Y,,,20220217,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,204823191,OT,,,204823191,1,,,5,MON,204823191,1,HIV infection
20482325,204823251,1,I,,20220207,20220216,20220216,EXP,,ZA-HETERO-HET2022ZA00346,HETERO,"Manickchund N, Du PC, John MA, Manzini TC, Gosnell BI,et al.. A case series of emtricitabine-induced pure red cell aplasia. Southern African Journal of HIV Medicine.. 2021;22(1):1-4",37,YR,,F,Y,,,20220217,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,204823251,OT,,,204823251,1,,,2,MON,204823251,1,HIV infection
20482343,204823431,1,I,,20220207,20220216,20220216,EXP,,ZA-HETERO-HET2022ZA00347,HETERO,"Manickchund N, Du PC, John MA, Manzini TC, Gosnell BI, et al.,. A case series of emtricitabine-induced pure red cell aplasia. Southern African Journal of HIV Medicine. 2021;22(1):1-4",23,YR,,F,Y,,,20220217,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,204823431,OT,,,204823431,1,,,4,MON,204823431,1,HIV infection
20482474,204824741,1,I,,20220207,20220217,20220217,EXP,,ZA-HETERO-HET2022ZA00344,HETERO,"Manickchund N, Du PC, John MA, Manzini TC, Gosnell BI, et al.,. A case series of emtricitabine-induced pure red cell aplasia. Southern African Journal of HIV Medicine. 2021;22(1):a1271",55,YR,,F,Y,,,20220217,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,204824741,OT,,,,,,,,,204824741,1,HIV infection
20482516,204825161,1,I,,20220207,20220217,20220217,EXP,,CO-HETERO-HET2022CO00367,HETERO,"Rojas Mejia DV, Zwiener RD, Cardona Villa R, Ramirez LF, Silva Espinosa DL, Serrano Reyes CD et al.,. Severe Cutaneous Adverse Reactions to Drugs in Latin America: The RACGRAD Study. J-Investig-Allergol-Clin-Immunol. 2021;31(4):322-331",,,,,Y,,,20220217,,HP,CO,CO,EFAVIRENZ,Drug reaction with eosinophilia and systemic symptoms,204825161,OT,,,,,,,,,204825161,1,Antiretroviral therapy
20494870,204948701,1,I,,20220214,20220221,20220221,EXP,,CA-ROCHE-3026280,ROCHE,,54,YR,,M,Y,,,20220221,,HP,CA,,SUSTIVA,Depression;Drug interaction,204948701,OT,,,,,,,,,204948701,1,Bipolar disorder
20495081,204950811,1,I,,20220214,20220221,20220221,EXP,,CA-ROCHE-3027855,ROCHE,,54,YR,,M,Y,,,20220221,,HP,CA,,SUSTIVA,Depression;Drug interaction,204950811,DE,,,,,,,,,204950811,1,Bipolar disorder
20503440,205034401,1,I,,20220214,20220222,20220222,EXP,,CA-TEVA-2022-CA-2009488,TEVA,,54,YR,A,M,Y,,,20220222,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities;Product use in unapproved indication,205034401,DE,,,,,,,,,205034401,1,HIV infection
20508516,205085161,1,I,,20220217,20220223,20220223,EXP,,DK-VIIV HEALTHCARE LIMITED-DK2022GSK029896,VIIV,"Bang D, Fonager J, Johansen IS.. Management of a human immunodeficiency virus case with discordant antiviral drug resistance profiles in cerebrospinal fluid compared with plasma: a case report. Journal of medical case reports. 2022;16 (62)",46,YR,,M,Y,,,20220223,,HP,DK,DK,EFAVIRENZ,Blood HIV RNA increased;CD4 lymphocytes decreased;CSF HIV escape syndrome;Confusional state;HIV-associated neurocognitive disorder;Neurological symptom;Pathogen resistance;Seizure;Treatment noncompliance;Viral mutation identified;Virologic failure,205085161,OT,,,,,,,,,205085161,1,HIV infection
20508520,205085201,1,I,,20220217,20220223,20220223,EXP,,DK-GLAXOSMITHKLINE-DK2022GSK029896,GLAXOSMITHKLINE,"Bang D, Fonager J, Johansen IS.. Management of a human immunodeficiency virus case with discordant antiviral drug resistance profiles in cerebrospinal fluid compared with plasma: a case report. Journal of medical case reports. 2022;16 (62)",46,YR,,M,Y,,,20220223,,HP,DK,DK,EFAVIRENZ,Blood HIV RNA increased;CD4 lymphocytes decreased;CSF HIV escape syndrome;Confusional state;HIV-associated neurocognitive disorder;Neurological symptom;Pathogen resistance;Seizure;Treatment noncompliance;Viral mutation identified;Virologic failure,205085201,OT,,,,,,,,,205085201,1,HIV infection
20509882,205098821,1,I,,20220215,20220224,20220224,EXP,,FR-JNJFOC-20220237289,JOHNSON AND JOHNSON,,,,A,,Y,,,20220224,,MD,FR,FR,EFAVIRENZ,Adverse event;Depression;Drug resistance;Gene mutation;Myocardial infarction;Virologic failure,205098821,OT,,,,,,,,,205098821,1,HIV infection
20527677,205276771,1,I,,20220215,20220228,20220228,EXP,,FR-GLAXOSMITHKLINE-FR2022035414,GLAXOSMITHKLINE,,,,A,,Y,,,20220228,,MD,FR,FR,EFAVIRENZ,Adverse event;Depression;Drug resistance;Gene mutation;Myocardial infarction;Virologic failure,205276771,OT,,,,,,,,,205276771,1,HIV infection
20527678,205276781,1,I,,20220215,20220228,20220228,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2022035414,VIIV,,,,A,,Y,,,20220228,,MD,FR,FR,EFAVIRENZ,Adverse event;Depression;Drug resistance;Gene mutation;Myocardial infarction;Virologic failure,205276781,OT,,,,,,,,,205276781,1,HIV infection
20530162,205301622,2,F,20070101,20220304,20220301,20220311,EXP,,CA-BAUSCH-BL-2022-005360,BAUSCH AND LOMB,"Harris M, Larsen G, Montaner J. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22 (14):1890-1891. doi:10.1097/QAD.0b013e32830e0169",44,YR,,M,Y,,,20220311,,MD,CA,CA,EFAVIRENZ,Drug interaction;Psychiatric decompensation,205301622,HO,,,205301622,5,20070626,20070522,355,DAY,205301622,1,Depression
20532042,205320421,1,I,,20220223,20220301,20220301,EXP,,CA-BAUSCH-BL-2022-005362,BAUSCH AND LOMB,,54,YR,,M,Y,,,20220301,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities;Product use in unapproved indication,205320421,DE,,,,,,,,,205320421,1,Bipolar disorder
20532718,205327181,1,I,,20220221,20220301,20220301,EXP,,BR-GILEAD-2022-0570872,GILEAD,"Fioroti C, Distenhreft J, Paulino BB, Lacchine K, Ramos DR, Seguro AC, Luchi WM. Tenofovir-induced renal and bone toxicity: report of two cases and literature review. Rev Inst Med Trop Sao Paulo.. 2022;64e10:1-7. doi:10.1590/S1678-9946202264010",62,YR,A,F,Y,,,20220301,,HP,BR,BR,EFAVIRENZ,Acute kidney injury;Bone disorder;Chronic kidney disease;Fanconi syndrome acquired;Hyperparathyroidism secondary;Multiple fractures;Nephropathy toxic,205327181,HO,,,205327181,2,,,4,YR,205327181,1,HIV infection
20538742,205387421,1,I,,20210826,20220302,20220302,EXP,,ES-JNJFOC-20210861785,JOHNSON AND JOHNSON,,,,C,M,Y,,,20220302,,HP,ES,EC,EFAVIRENZ,Histoplasmosis disseminated;Treatment noncompliance,205387421,DE,,,,,,,,,205387421,1,Histoplasmosis disseminated
20538880,205388802,2,F,20070101,20220304,20220302,20220311,EXP,,CA-GLAXOSMITHKLINE-CA2022GSK037442,GLAXOSMITHKLINE,"Harris M, Larsen G, Montaner J.. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22(14):1890-1891",44,YR,,M,Y,,,20220311,,MD,CA,CA,EFAVIRENZ,Drug interaction;Psychiatric decompensation,205388802,HO,,,205388802,9,20060602,20070522,355,DAY,205388802,1,Depression
20540104,205401042,2,F,,20220111,20220302,20220322,EXP,,CA-JNJFOC-20211128009,JOHNSON AND JOHNSON,,,,,,Y,,,20220323,,HP,CA,CA,EFAVIRENZ,Ascites;Hepatic encephalopathy;Hepatocellular carcinoma;Spontaneous bacterial peritonitis,205401042,OT,,,,,,,,,205401042,1,HIV infection
20557900,205579001,1,I,,20220224,20220307,20220307,EXP,,DK-AUROBINDO-AUR-APL-2022-006891,AUROBINDO,"Bang D, Fonager J, Johansen IS... Management of a human immunodeficiency virus case with discordant antiviral drug resistance profiles in cerebrospinal fluid compared with plasma: a case report.. Journal of medical case reports.. 2022;16 (62)",46,YR,,M,Y,,,20220307,,HP,DK,DK,EFAVIRENZ,Blood HIV RNA increased;CD4 lymphocytes decreased;CSF HIV escape syndrome;Confusional state;HIV-associated neurocognitive disorder;Neurological symptom;Pathogen resistance;Seizure;Treatment noncompliance;Viral mutation identified;Virologic failure,205579001,OT,,,,,,,,,205579001,1,HIV infection
20557964,205579641,1,I,,20220221,20220307,20220307,EXP,,IN-CIPLA (EU) LIMITED-2022IN01197,CIPLA,"Sinha P, Ayub A, Lekshmi Priya K, Madakshira MG, MN A, Koshy V.. AIDS-Associated psoriasiform dermatitis - An uncommonly reported entity occurring along with drug reaction with eosinophilia and systemic symptoms (DRESS). Indian journal of dermatology. 2021;66 (6):1 to 5",,,,,Y,,,20220307,,HP,IN,IN,EFAVIRENZ,Drug reaction with eosinophilia and systemic symptoms,205579641,OT,,,,,,,,,205579641,1,HIV infection
20559230,205592301,1,I,,20220222,20220307,20220307,EXP,,US-MACLEODS PHARMA UK LTD-MAC2022034654,MACLEODS,"Hammond KP, Nielsen C, Linnebur SA, Langness JA, Ray G, Maroni P, Kiser JJ. Priapism induced by boceprevir-CYP3A4 inhibition and ?-adrenergic blockade: case report. Clinical Infectious Diseases. 2014;58(1):e35-8",,,,,Y,,,20220305,,HP,US,US,Efavirenz 600 mg/Emtricitabine 200 mg/tenofovir disoproxil 300 mg,Drug interaction;Priapism,205592301,OT,,,,,,,,,205592301,1,Product used for unknown indication
20561430,205614301,1,I,20181214,20210308,20220307,20220307,EXP,CZ-VIIV HEALTHCARE LIMITED-CZ2021EME053964,NVSC2021CZ053413,NOVARTIS,,53,YR,,M,Y,,,20220307,,MD,CZ,CZ,EFAVIRENZ,Drug ineffective;Dysuria;HIV infection;Immunodeficiency;Kaposi's sarcoma;Laboratory test abnormal;Lymphoedema;Multiple-drug resistance;Neoplasm progression;Pancytopenia;Pyrexia;Skin lesion;Toxicity to various agents;Urinary tract infection;Virologic failure,205614301,OT,,,205614301,2,20000403,19990322,434,DAY,205614301,1,Opportunistic infection prophylaxis
20570335,205703351,1,I,,20220308,20220309,20220309,EXP,,CA-ABBVIE-22K-028-4307459-00,ABBVIE,,,,,M,Y,,,20220309,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction,205703351,OT,,,,,,,,,205703351,1,Product used for unknown indication
20570887,205708871,1,I,,20220223,20220309,20220309,EXP,,BR-MACLEODS PHARMACEUTICALS US LTD-MAC2022034677,MACLEODS,"Fioroti CEA, Distenhreft JIQ, Paulino BB, Lacchine K, Ramos DR, Seguro AC, Luchi WM.. Tenofovir-induced renal and bone toxicity: report of two cases and literature review. Journal of the s?o paulo institute of tropical medicine. 2022;64:7",,,,,Y,,,20220309,,HP,BR,BR,EFAVIRENZ,Acute kidney injury;Bone density decreased;Fanconi syndrome;Fracture;Hyperparathyroidism secondary;Musculoskeletal toxicity;Nephropathy toxic;Vitamin D deficiency,205708871,HO,,,,,,,,,205708871,1,HIV test positive
20571079,205710791,1,I,,20220228,20220309,20220309,EXP,,BR-STRIDES ARCOLAB LIMITED-2022SP002280,STRIDES,"Fioroti CEA, Distenhreft JIQ, Paulino BB, Lacchine K, Ramos DR, Seguro AC, et al.. Tenofovir-induced renal and bone toxicity: report of two cases and literature review. [Review].. Rev-Inst-Med-Trop-Sao-Paulo. 2022",62,YR,,F,Y,,,20220309,,HP,BR,BR,EFAVIRENZ,Acute kidney injury;Bone density decreased;Chronic kidney disease;Fanconi syndrome;Fracture;Hyperparathyroidism secondary;Vitamin D deficiency,205710791,HO,,,,,,,,,205710791,1,HIV infection
20574834,205748342,2,F,,20220302,20220310,20220315,EXP,,FR-AUROBINDO-AUR-APL-2022-007338,AUROBINDO,"Landman R, de Truchis P, Assoumou L, Lambert S, Bellet J, Amat K, et al... A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial.. The Lancet HIV.. 2022;9 (2):e79-90",,,A,,Y,,,20220315,,MD,FR,FR,EFAVIRENZ,Adverse event;Depression;Drug resistance;Gene mutation;Myocardial infarction;Pathogen resistance;Virologic failure,205748342,OT,,,,,,,,,205748342,1,HIV infection
20580969,205809691,1,I,,20220301,20220311,20220311,EXP,,DK-009507513-2203DNK000839,MERCK,"Bang D, Fonager J, Johansen IS. Management of a human immunodeficiency virus case with discordant antiviral drug resistance profiles in cerebrospinal fluid compared with plasma: a case report. Journal of medical case reports. 2022;16 (62)",46,YR,,M,Y,,,20220311,,HP,DK,DK,EFAVIRENZ,HIV-associated neurocognitive disorder;Pathogen resistance;Treatment noncompliance;Virologic failure,205809691,OT,,,,,,,,,205809691,1,HIV infection
20581656,205816561,1,I,,20220228,20220311,20220311,EXP,,IN-CIPLA LTD.-2022IN01512,CIPLA,Singh RK. Images in Clinical Tropical Medicine Diffuse Non-Genital Cutaneous Warts. Am. J. Trop. Med. Hyg. 2022;106(2):378 to 379,,,,,Y,,,20220311,,HP,IN,IN,EFAVIRENZ,Drug resistance;Therapeutic product effect decreased,205816561,OT,,,,,,,,,205816561,1,HIV infection
20582391,205823911,1,I,,20220228,20220311,20220311,EXP,,DK-JNJFOC-20220301083,JOHNSON AND JOHNSON,,46,YR,A,M,Y,,,20220311,,HP,DK,DK,EFAVIRENZ,Blood HIV RNA increased;CD4 lymphocytes decreased;CSF HIV escape syndrome;Confusional state;HIV-associated neurocognitive disorder;Neurological symptom;Pathogen resistance;Seizure;Treatment noncompliance;Viral mutation identified;Virologic failure,205823911,OT,,,,,,,,,205823911,1,HIV infection
20587130,205871302,2,F,,20220316,20220314,20220321,EXP,,US-CIPLA LTD.-2022US01631,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S et al.. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2022;1 to 11",,,,,Y,,,20220321,,HP,US,US,EFAVIRENZ,Drug resistance;Treatment noncompliance,205871302,OT,,,205871302,1,2007,,,,205871302,1,HIV infection
20587147,205871471,1,I,,20220302,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01632,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S et al.. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2022;1 to 11",,,,,Y,,,20220314,,HP,US,US,EFAVIRENZ,Drug resistance,205871471,OT,,,,,,,,,205871471,1,HIV infection
20587173,205871731,1,I,,20220302,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01633,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S  et al.. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2022;1 to 11",,,,,Y,,,20220314,,HP,US,US,EFAVIRENZ,Drug resistance,205871731,OT,,,,,,,,,205871731,1,HIV infection
20587176,205871761,1,I,,20220302,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01634,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S  et al.. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2022;1 to 11",,,,,Y,,,20220314,,HP,US,US,EFAVIRENZ,Drug resistance,205871761,OT,,,,,,,,,205871761,1,HIV infection
20587178,205871781,1,I,,20220302,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01635,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S et al. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2021;1 to 11",,,,,Y,,,20220314,,HP,US,US,EFAVIRENZ,Drug resistance,205871781,OT,,,,,,,,,205871781,1,HIV infection
20587182,205871821,1,I,,20220302,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01636,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S et al. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2022;1 to 11",,,,,Y,,,20220314,,HP,US,US,EFAVIRENZ,Drug resistance,205871821,OT,,,,,,,,,205871821,1,HIV infection
20587186,205871861,1,I,,20220302,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01637,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani SF, Howison M, Aung S, et.al. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Infections Diseases Society of America. 2021;1 to 11",,,,,Y,,,20220314,,HP,US,US,EFAVIRENZ,Drug resistance,205871861,OT,,,,,,,,,205871861,1,HIV infection
20587259,205872591,1,I,,20220302,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01639,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S et al. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2022;1 to 11",,,,,Y,,,20220314,,HP,US,US,EFAVIRENZ,Drug resistance,205872591,OT,,,,,,,,,205872591,1,HIV infection
20587328,205873281,1,I,,20220302,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01626,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S  et al.. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2022;1 to 11",,,,,Y,,,20220314,,HP,US,US,EFAVIRENZ,Drug resistance,205873281,OT,,,,,,,,,205873281,1,HIV infection
20587391,205873911,1,I,,20220302,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01643,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S et al. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2021;1 to 11",,,,,Y,,,20220314,,HP,US,US,EFAVIRENZ,Drug resistance,205873911,OT,,,,,,,,,205873911,1,HIV infection
20587392,205873921,1,I,,20220302,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01644,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S et al. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2022;1 to 11",,,,,Y,,,20220314,,HP,US,US,EFAVIRENZ,Drug resistance,205873921,OT,,,,,,,,,205873921,1,HIV infection
20587397,205873971,1,I,,20220302,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01642,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S  et al.. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2022;1 to 11",,,,,Y,,,20220314,,HP,US,US,EFAVIRENZ,Drug resistance,205873971,OT,,,,,,,,,205873971,1,HIV infection
20587399,205873991,1,I,,20220302,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01628,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S et al. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2022;1 to 11",,,,,Y,,,20220314,,HP,US,US,EFAVIRENZ,Drug resistance,205873991,OT,,,205873991,3,2007,,,,205873991,1,HIV infection
20587413,205874131,1,I,,20220302,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01630,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S et al.,. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Infectious Diseases Society of America. 2021;1 to 11",,,,,Y,,,20220314,,HP,US,US,EFAVIRENZ,Drug resistance,205874131,OT,,,,,,,,,205874131,1,HIV infection
20587414,205874141,1,I,,20220302,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01629,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S et al.. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Open Forum Infectious Diseases. 2022;1 to 11",,,,,Y,,,20220314,,HP,US,US,EFAVIRENZ,Drug resistance,205874141,OT,,,,,,,,,205874141,1,HIV infection
20587632,205876321,1,I,,20220302,20220314,20220314,EXP,,US-CIPLA LTD.-2022US01638,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S et al.. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Statewide HIV Transmitted Resistance. 2021;1 to 16",,,,,Y,,,20220314,,HP,US,US,EFAVIRENZ,Drug resistance,205876321,OT,,,,,,,,,205876321,1,HIV infection
20591244,205912442,2,F,20211216,20220318,20220314,20220325,EXP,,DE-TAKEDA-2022TUS015510,TAKEDA,,,,A,M,Y,,,20220325,,HP,DE,DE,EFAVIRENZ,C-reactive protein increased,205912442,HO,,,205912442,1,20190107,20211227,38,DAY,205912442,1,Prophylaxis
20591668,205916681,1,I,,20220303,20220314,20220314,EXP,,CA-BAXTER-2022BAX005146,BAXTER,,,,,,Y,,,20220314,,HP,CA,CA,EFAVIRENZ,Acute kidney injury;Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Blood bilirubin increased;Cerebral ischaemia;Cystitis noninfective;Drug interaction;Febrile neutropenia;Haematuria;Infection;Myalgia;Pulmonary embolism;Seizure;Thrombosis;Tumour lysis syndrome;Vomiting,205916681,OT,,,,,,,,,205916681,1,Diffuse large B-cell lymphoma
20591743,205917431,1,I,,20220307,20220314,20220314,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-036994,BRISTOL MYERS SQUIBB,"Ragni MV, Majerus E, Giermasz A, Fong S, Yates B, Scheeler S, et al. Valoctocogene roxaparvovec gene transfer in participants with HIV. Haemophilia. 2022;28(Suppl 1):101-2",,,,M,Y,,,20220314,,HP,US,US,EFAVIRENZ,Drug interaction;Hepatocellular injury,205917431,OT,,,,,,,,,205917431,1,HIV infection
20592844,205928441,1,I,20200115,20220308,20220315,20220315,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-037237,BRISTOL MYERS SQUIBB,,18,YR,,F,Y,,,20220315,,HP,ZW,ZW,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,205928441,OT,,,205928441,1,20190122,,,,205928441,1,HIV infection
20595035,205950351,1,I,20110101,20220302,20220315,20220315,EXP,,US-CIPLA (EU) LIMITED-2022US01627,CIPLA,"Novitsky V, Kantor R, Steingrimsson J, Gillani FS, Howison M, Aung S et al. Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA. Statewide HIV Transmitted Resistance. 2022;1 to 11",,,,,Y,,,20220315,,HP,US,US,EFAVIRENZ,Drug resistance;Exposure during pregnancy;Toxicity to various agents;Viral load increased,205950351,OT,,,205950351,1,2012,2013,,,205950351,1,HIV infection
20596286,205962861,1,I,,20220307,20220315,20220315,EXP,,IN-MYLANLABS-2022M1019603,MYLAN,"Phatak UA, Badakh DK. Squamous cell carcinoma of the rectum in an HIV-1 patient on antiretroviral therapy. J-Cancer-Res-Ther 2021;17(6):1556-1558.",56,YR,,M,Y,,,20220315,,MD,IN,IN,EFAVIRENZ,Deep vein thrombosis;Escherichia sepsis;Hypokalaemia;Hypoproteinaemia;Intestinal obstruction;Liver function test abnormal;Multiple organ dysfunction syndrome;Pneumonia;Renal function test abnormal,205962861,DE,,,205962861,3,,,6,YR,205962861,1,Rectal cancer
20601370,206013701,1,I,,20220307,20220316,20220316,EXP,,IL-STRIDES ARCOLAB LIMITED-2022SP002540,STRIDES,"David D, Kedem E, Turner D, Levy I, Elbirt DG, Shahar E, et al.. Long term dual antiretroviral therapy: A real life retrospective countrywide Israeli study.. PLOS-One.. 2021;16(10)",,,,F,Y,,,20220316,,HP,IL,IL,EFAVIRENZ,Cardiovascular disorder;Renal disorder,206013701,OT,,,,,,,,,206013701,1,HIV infection
20601388,206013882,2,F,20201201,20220316,20220316,20220318,EXP,,ZA-GILEAD-2022-0573405,GILEAD,,21,YR,A,F,Y,,,20220318,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,206013882,OT,,,206013882,1,20180212,,,,206013882,1,HIV infection
20601438,206014382,2,F,,20220315,20220316,20220323,EXP,,ZA-CIPLA (EU) LIMITED-2022ZA01722,CIPLA,"Siddiqui N, Mansfield BS, Olmesdahl NP, Swart P, Nel J. A Severe Case of Molluscum Contagiosum Immune Reconstitution Inflammatory Syndrome in a Patient with Human Immunodeficiency Virus. European Journal of Case Reports in Internal Medicine. 2022;9 (1)",,,,,Y,,,20220323,,MD,ZA,ZA,EFAVIRENZ,Acute kidney injury;Condition aggravated;Immune reconstitution inflammatory syndrome;Molluscum contagiosum;Normocytic anaemia;Paradoxical drug reaction,206014382,DE,,,,,,,,,206014382,1,Antiretroviral therapy
20601791,206017911,1,I,,20220303,20220316,20220316,EXP,,ZA-JNJFOC-20220252052,JOHNSON AND JOHNSON,,,,A,,Y,,,20220316,,HP,ZA,ZA,EFAVIRENZ,Adverse event;Drug resistance;Intentional product use issue;Off label use,206017911,OT,,,206017911,1,,,26,WK,206017911,1,Tuberculosis
20602073,206020731,1,I,,20220310,20220316,20220316,EXP,,SG-GILEAD-2022-0573423,GILEAD,,48,YR,A,M,Y,,,20220316,,CN,SG,SG,EFAVIRENZ,Liver injury,206020731,OT,,,206020731,1,2017,,,,206020731,1,HIV infection
20602708,206027082,2,F,20200115,20220316,20220316,20220323,EXP,,ZW-VIIV HEALTHCARE LIMITED-ZW2022GSK047270,VIIV,,18,YR,,F,Y,,,20220323,,HP,ZW,ZW,SUSTIVA,Abortion spontaneous;Exposure during pregnancy,206027082,OT,,,206027082,1,20190122,20191217,329,DAY,206027082,1,HIV infection
20602710,206027102,2,F,20200115,20220316,20220316,20220323,EXP,,ZW-GLAXOSMITHKLINE-ZW2022GSK047270,GLAXOSMITHKLINE,,18,YR,,F,Y,,,20220323,,HP,ZW,ZW,SUSTIVA,Abortion spontaneous;Exposure during pregnancy,206027102,OT,,,206027102,1,20190122,20191217,329,DAY,206027102,1,HIV infection
20612453,206124531,1,I,,20220310,20220318,20220318,EXP,,CA-MYLANLABS-2022M1020580,MYLAN,,54,YR,,M,Y,,,20220318,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,206124531,DE,,,,,,,,,206124531,1,Bipolar disorder
20618184,206181841,1,I,20180101,20220316,20220321,20220321,EXP,,DE-GILEAD-2022-0574264,GILEAD,,29,YR,A,F,Y,,,20220321,,MD,DE,DE,EFAVIRENZ,Anxiety;COVID-19;Central nervous system lesion;Cervical dysplasia;Depressed mood;Depression;Fear of death;Hemiparesis;Herpes zoster;Iron deficiency anaemia;Loss of consciousness;Panic reaction;Peroneal nerve palsy;Sleep disorder;Thinking abnormal;Toxoplasmosis,206181841,OT,,,206181841,1,201812,201812,,,206181841,1,HIV infection
20641489,206414891,1,I,,20220315,20220328,20220328,EXP,,ZA-AUROBINDO-AUR-APL-2022-008940,AUROBINDO,"Siddiqui N, Mansfield BS, Olmesdahl NP, Swart P, Nel J.. A Severe Case of Molluscum Contagiosum Immune Reconstitution Inflammatory Syndrome in a Patient with Human Immunodeficiency Virus.. European Journal of Case Reports in Internal Medicine. 2022;9(1)",57,YR,,M,Y,,,20220328,,MD,ZA,ZA,EFAVIRENZ,Condition aggravated;Immune reconstitution inflammatory syndrome;Molluscum contagiosum;Paradoxical drug reaction,206414891,HO,,,,,,,,,206414891,1,HIV infection
20641852,206418521,1,I,20150329,20220318,20220328,20220328,EXP,,US-GILEAD-2016-0242362,GILEAD,,,,,M,Y,,,20220328,,MD,US,PE,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug eruption,206418521,OT,,,,,,,,,206418521,1,HIV infection
20642663,206426631,1,I,,20220318,20220328,20220328,EXP,,CA-TEVA-2022-CA-2020215,TEVA,,54,YR,A,M,Y,,,20220328,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,206426631,OT,,,,,,,,,206426631,1,HIV infection
20643495,206434951,1,I,,20220315,20220328,20220328,EXP,,ZA-MACLEODS PHARMACEUTICALS US LTD-MAC2022034946,MACLEODS,"Siddiqui N, Mansfield BS, Olmesdahl NP, Swart P, Nel J.. A Severe Case of Molluscum Contagiosum Immune Reconstitution Inflammatory Syndrome in a Patient with Human Immunodeficiency Virus. European Journal of Case Reports in Internal Medicine. 2022;9(1)",,,,,Y,,,20220328,,MD,ZA,ZA,EFAVIRENZ,Condition aggravated;Death;Immune reconstitution inflammatory syndrome;Molluscum contagiosum;Paradoxical drug reaction,206434951,DE,,,,,,,,,206434951,1,HIV infection
20644749,206447491,1,I,,20220323,20220328,20220328,EXP,,CA-BAUSCH-BL-2022-007533,BAUSCH AND LOMB,,54,YR,,M,Y,,,20220328,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Loss of personal independence in daily activities,206447491,OT,,,,,,,,,206447491,1,Bipolar disorder
20645596,206455961,1,I,,20220318,20220328,20220328,EXP,,CA-TEVA-2022-CA-2020214,TEVA,,54,YR,A,M,Y,,,20220328,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Loss of personal independence in daily activities,206455961,DE,,,,,,,,,206455961,1,HIV infection
20645800,206458002,2,F,20211201,20220323,20220328,20220330,EXP,,BR-ORGANON-O2203BRA002402,ORGANON,,39,YR,,F,Y,,,20220330,,MD,BR,BR,EFAVIRENZ,Abortion of ectopic pregnancy;Ectopic pregnancy with contraceptive device;Unintended pregnancy,206458002,OT,,,206458002,1,202010,,,,206458002,2,Antiretroviral therapy
20649358,206493581,1,I,,20220322,20220329,20220329,EXP,,IL-JNJFOC-20220348654,JOHNSON AND JOHNSON,,,,E,,Y,,,20220329,,HP,IL,IL,EFAVIRENZ,Cardiovascular disorder;Drug interaction;Gastrointestinal disorder;Hyperlipidaemia;Hypersensitivity;Nervous system disorder;Osteoporosis;Renal disorder,206493581,OT,,,,,,,,,206493581,1,HIV infection
20653786,206537861,1,I,,20220323,20220330,20220330,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022GSK056083,VIIV,,54,YR,,M,Y,,,20220330,,MD,CA,CA,EFAVIRENZ,Depression;Drug interaction;Loss of personal independence in daily activities,206537861,DE,,,,,,,,,206537861,1,Bipolar disorder
20653790,206537901,1,I,,20220323,20220330,20220330,EXP,,CA-GLAXOSMITHKLINE-CA2022GSK056083,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20220330,,MD,CA,CA,EFAVIRENZ,Depression;Drug interaction;Loss of personal independence in daily activities,206537901,HO,,,,,,,,,206537901,1,Bipolar disorder
20654193,206541931,1,I,,20220325,20220330,20220330,EXP,,DK-MYLANLABS-2022M1022948,MYLAN,"Bang D, Fonager J, Johansen IS... Management of a human immunodeficiency virus case with discordant antiviral drug resistance profiles in cerebrospinal fluid compared with plasma: a case report.. Journal of medical case reports. 2022;16(62)",46,YR,,M,Y,,,20220330,,HP,DK,DK,EFAVIRENZ,Blood HIV RNA increased;CD4 lymphocytes decreased;CSF HIV escape syndrome;Confusional state;HIV-associated neurocognitive disorder;Neurological symptom;Pathogen resistance;Seizure;Treatment noncompliance;Viral mutation identified;Virologic failure,206541931,OT,,,,,,,,,206541931,1,HIV infection
20655394,206553941,1,I,,20220323,20220330,20220330,EXP,,CA-ABBVIE-11P-028-0710272-00,ABBVIE,,54,YR,,M,Y,,,20220330,,CN,CA,CA,SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities;Product use in unapproved indication,206553941,DE,,,,,,,,,206553941,1,Product used for unknown indication
20660220,206602201,1,I,20180403,20220324,20220331,20220331,EXP,,DE-SHIRE-DE201816687,TAKEDA,,46,YR,,,Y,104,KG,20220331,,MD,DE,DE,EFAVIRENZ,Gastric ulcer,206602201,OT,,,206602201,1,20090901,20120215,2329,DAY,206602201,1,Prophylaxis
7408901,74089012,2,F,,20220125,20100603,20220201,EXP,,US-GILEAD-2010-0029436,GILEAD,,52,YR,A,M,Y,,,20220201,,HP,US,US,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,74089012,OT,,,74089012,1,,,2470,DAY,74089012,1,HIV infection
7609977,760997726,26,F,20061128,20220201,20100928,20220215,EXP,,JP-JNJFOC-20100907113,JOHNSON AND JOHNSON,,49,YR,A,M,Y,,,20220215,,MD,JP,JP,EFAVIRENZ,Anaemia;Dyslipidaemia;Hepatocellular carcinoma;Hyperbilirubinaemia;Osteoporosis;Pyelonephritis,760997726,HO,,,760997726,1,20061111,19970924,280,DAY,760997726,1,HIV infection
9204695,92046954,4,F,20070101,20220321,20130402,20220325,EXP,,JP-GILEAD-2011-0039952,GILEAD,D  Watanabe. Immune reconstitution to parvovirus B19 and resolution of anemia in a patient treated with highly active antiretroviral therapy.. Journal of Infection and Chemotherapy. 2011;17:283 - 287,54,YR,A,M,Y,,,20220325,,HP,JP,JP,EFAVIRENZ,Aplasia pure red cell;Immune reconstitution inflammatory syndrome,92046954,OT,,,92046954,1,200701,,,,92046954,1,HIV infection
